Fire Safety Encyclopedia

A science that studies the mechanism of action of a drug. The meaning of the word pharmacology. Medicines are dosed

PHARMACOLOGY (from the Greek pharmakon-medicine, poison and logos-word, doctrine), the science of the action of medicinal substances on a living organism. The very word F. first appeared in the 17th century; in 1693 Dale entitled his work on pharmacognosy Pharmacologia, s. manuductio ad materiam medicam ". Only almost a hundred years later, Gren published (in 1790) a manual on medicinal substances with the doctrine of their therapy. and fiziol. acting under the title Handbuch der Pharmacologie. Experimental physics developed in the early days thanks to the work of physiologists (Claude Bernard, Stannius, Schiff, and others); the first school of pharmacologists arose under the leadership of Buchheim, who created the first pharmacol in 1847. laboratory at Dorpat University. An experimental method for examining the action of medicinal substances consists in studying the effect on healthy animals, on their systems and individual organs; research is also often performed on unicellular organisms such as ciliates, fungi, bacteria; Plants are often the test material. After the study of pharmacodynamics in healthy animals, the study of the funds is continued on sick animals, since the susceptibility of healthy and diseased organisms is often not the same. With this research order, it is often possible to outline the foundations for the therapist. the use of the drug, due to which the suitability, value and possible ways of using the studied substance in the patient become even more clear. The last stage of the experimental study of the substance takes place already in the clinics, where the therapy is determined. the action of the drug substance with all its features and side effects. According to the same plan, medicinal substances that have been used for a long time are investigated, since it is required to establish the mechanism of their action, the fate in the body, the place of occurrence in it, the pathway of excretion, cumulative or synergistic effects, etc., provided that the body is ill. The subject of pharmacol. researches can be also such substances, to-rye are not used in therapy, but deserve attention, for example. due to its toxicity. By its content, F. is subdivided into the so-called. general F. and particular F. The content of general F. is, in addition to defining the subject and objectives of F., setting the boundaries of F. in a number of disciplines that study the various properties of medicinal substances, clarifying the essence of the local and general, resp. resorptive, the action of medicinal or poisonous substances on the body, reflex, selective or specific, elucidation of the various phases of action and various conditions on the part of the body and on the part of the medicinal substance that affect the manifestation of the action of drugs or poisons, taking into account the nature of their action, routes of administration, distribution in the body and ways of excretion from the body, as well as those changes, to-rye undergo drugs or poisons in the body. That. in the department of general F., questions of general toxicology are also found. - Part F. studies individual medicinal substances in relation to their action on the whole organism and on its systems, on animal organs in situ, on isolated organs, on exchange substances, at t °; studies and all the issues specified in general F., but with respect to each medicinal (resp. poisonous) substance. Pharmacol. the study captures the life of an animal under conditions 1) the initial action of the drug-fiziol. action; further 2) the developed action of the drug, but still within the boundaries of b. or m. a healthy state of the body; such an effect is close to the action of a medicine used in the so-called. secondary therapists. doses; in both cases, the phenomena arising from the influence of a medicinal substance are characterized by their reversibility; finally, the drug is being studied under conditions where its action disturbs the usual state of equilibrium and signs of toxic action appear; the reaction may be still reversible in these cases, but not always; 3) when the body dies from the changes that have occurred under the influence of the introduced substance (lethal doses), the reaction is irreversible. Measures to help a patient poisoned with a medicine are also developed by F. Private F. establishes the principles of indications for therapy. the appointment of a medicinal substance, as well as contraindications under certain conditions on the part of the b-nogo, and is in close connection with physiology and fiziol. chemistry, using their methodology and all the results and conclusions. F. studies the effect of drugs on the sick organism, therefore F.'s connection with stalemate. physiology also seems to be quite natural, especially since the most diverse pathogens can also be caused by drugs. phenomena in the body. In turn, F. contributes to the success and development of these disciplines, serving them with his data on medicinal and poisonous substances used to study various fiziol. and US Pat. functions and processes. Bacteriology and microbiology, in addition to their contact with F. on problems of a general biological nature, work together on the pharmacodynamic properties of medicinal sera, the action of toxins and endotoxins, protective sera, antiseptic and disinfectants, and others. Morfol. honey. sciences led by a microscope, anatomy also mutually £ 29 with F. serving each other's needs; the first provide F. with a material substrate, the action of drugs and poisons on which is studied by her, and the latter, with her research, comes to the aid of the first not only in determining the dynamic value of the studied devices, but also their morfol. structures (Lavrentiev). F. owes its development and success to chemistry and physics, with which its connection is growing stronger and is the foundation of further progress of pharmacol. knowledge. Physics teaching and colloidal chemistry in the most radical way affects the solution of pharmacol problems. character on the intimate side of the action of medicinal substances on the cell and on the body as a whole, on the distribution of medicinal substances in the body and on the points of application of the action of poisons, on the conditions of action of drugs in the body, on changes in blood and tissues, etc. particular pharmaceutical chemistry with its methods of synthetic production of medicinal substances helped to resolve the issue outlined by Buchheim, about the dependence of the action of drugs and poisons on their physical and chemical. properties and made it possible to establish the principle of similarity between pharmacol. actions in chemically related bodies. The various centuries-old use of medicines "with a therapeutic purpose has connected F. with all types of therapy. F., serving clinics, in turn seeks all the latest means, as well as new things about the substances used, to conduct an analysis through a wedge. medicine is established through the department of phyto-toxicology, which at the present time has gained great importance, especially in the USSR, where the task of eliminating hazards affecting the health and productivity of workers was put in full swing. , in particular, professional hygiene and food hygiene, having come to grips with the study of the pharmacodynamics of many substances, the action of which can adversely affect the health of workers under certain conditions of production or nutrition, or the use of prepared items, work hand in hand with F. In a particularly close F. is in contact with pharmaceutical chemistry, with pharmaceutical formulation and, through the latter, with technology l medicinal preparations and forms; the data of these disciplines are also largely developed by pharmacology. Modern physics concentrates its attention on the following tasks: 1) to find and bring together those fundamental laws that will make it possible to determine the nature and direction of the action of drugs on the body; 2) to study the transformation of drugs in the body of animals, in particular in humans, the place of distribution in the body, the routes of excretion and action of both the introduced substance and its transformation products in the body, in connection with the study of the environment in which the medicinal substance acts. The most important particular problems in this aspect are as follows: 1) the problem of the action of heavy metals in connection with electrolytic. dissociation of their compounds; 2) the question of pharmacol. irritants in connection with the issues of isoiony and isotony of the environment surrounding the cell; 3) the problem of anesthesia in connection with the work on the means for inhalation, intravenous and rectal anesthesia; 4) the question of sleeping pills; 5) poisons of the autonomic nervous system with sympathicotropic and parasympathic-tropic action; 6) study of foxglove ,. ergot and other herbal preparations; 7) the synergistic action of substances and the ratio in action between simple mixtures and compounds; 8) the phenomenon of getting used to certain drugs or poisons; 9) the question of potential poisons; 10) study of the strength, speed and duration of action of drugs; 11) development of the problem of the relationship between the chemical structure and pharmacological action of medicinal and poisonous substances; 12) study of natural camphor (obtained from various plants) and synthetic; 13) the problem of the penetration and circulation of iodine in the body and its effect on the metabolism, on nutrition and on the structure of tissues; 14) the problem of the use of drugs for preventive purposes; 15) the study of the effect of medicinal substances introduced into the body in minimal quantities; 16) the effect of medicinal substances depending on their dosage form; 17) the problems of hormone therapy, organotherapy, lysis-therapy, protein therapy; 18) the problem of studying traditional medicine. , biological and colloidal chemistry, microchemistry, by the method of biological analysis, in many cases so adapting and specializing them, that in essence this or that method is strengthened by F. for F., since the technique is used to study medicinal and toxic substances. Having ascertained the quality and intensity of the pharmacological action of the medicinal agent, then it is subjected to a wedge, testing and application. - History of pharmacol. the experimental method also knows the so-called. therapist. methods, which include: 1) the most ancient therapy. an empirical method, crudely experienced, which gave a huge, but not covered by scientific theory, material about drugs; 2) statistical method; applied with all the severity of scientific criticism, it becomes a necessary and strict judge of modern experimental laboratory and wedge research methods of medicines; 3) the symptomatic method, which consists in recording observations on the elimination or relief of specific painful symptoms of diseases with the help of drugs, while the main cause and essence of the disease remains unattended; 4) the method of suggestion, when the action of a medicine is viewed not as a result of the influence of certain material forces, but as a means of influencing the psyche of a god; therefore, the taste of the medicine, its smell, especially the novelty of the drug and the novelty of the method of administration, are highly valued in the method of suggestion. While the experimental method for the study of medicinal substances from the 40s of the 19th century. especially began to be cultivated in Germany, French scientists concentrated the study of medicinal substances in clinics, using mainly therapy for this. methods. This is how two main pharmacol schools were created; the French were joined by specialists in England and Italy, and the German by scientists from other European countries, in particular by the Russians, who received and supplemented their special education usually in Germany. The development of questions of pharmacodynamics in laboratories was so successful that the German school of pharmacy * kologov transferred the entire doctrine of the action of drugs to the laboratory, focusing the study of drugs only on animals; in the 60s of the 19th century. German pharmacologists even expressed the opinion that F. did not care whether the substance under study would be used in clinics, it is only important which phyzol. the studied substance has an effect on the body. This is the view of pharmaco-physiologists. The present scientific philosophy is far from such a view. In crust, time and French pharmacol. the school, under the leadership of Tiffeneau, Fourneau and Florence, significantly deepened its research on medicinal substances by studying them in an experimental laboratory method on animals, while at the same time carrying out conventional therapies on the same means. study methods. In the direction of the clip, the examination of medicines in a German school began to deviate in the 70s of the 19th century, when Schmiedeberg “, together with the clinician Naunin, organized a pharmacol. a magazine that gives space to articles with a wedge, analysis of the effect of drugs; in the second "decade of the present. century, represented by G. Meyer (Vienna), the German school raised the question of the need to attach a wedge, departments to pharmacological institutes to study the pharmacodynamic properties of medicinal substances in all their diversity of action on humans. Heutmer (Gettin-gen, Berlin) organized joint teaching with a therapist at the university on some issues of the action of drugs.Bornstein (Hamburg) systematically studied the effect of drugs in parallel in a laboratory on animals and in a clinic on humans. In Russia, Bogoslovsky (Moscow ) back in the 90s of the 19th century he furnished the teaching of physics in such a way that students saw the effect of drugs not only on animals, but also on patients in the clinic. Kravkov followed the same path in his research. Department of Pharmacology 1 MMI ( Nikolaev) raised the question of the need to reform the teaching of F. in the direction of the parallel study of medicinal substances by students in the laboratory on animals and in the clique in humans. The newest medicinal substances produced by the Soviet pharmaceutical. industry, are studied experimentally in pharmacol. laboratories and clinics in patients and only after such a test are recommended for medical use. Prominent therapists (Pletnev) are in favor of the timeliness of the experimental study of drugs in humans, and not only in animals. In Italy, where the direction of the French school was previously dominant in France, and later, under the influence of the German school, which educated a large number of modern Italian pharmacologists (Baldoni, Cervello), the doctrine of the action of drugs strongly deviated towards laboratory research. In England, Cuslmy combined experimental and therapy in drug research. methods and was able to turn the English F. to this combined path. The Japanese school of pharmacologists, headed by Morishima and Hayashi, students of the German experimental school, works using both experimental laboratory and clinical-therapeutic methods. American pharmacologists are also working in the same direction. In the USSR, Kravkov created a prominent Leningrad school of pharmacologists, now headed by Likhachev. School Kazan (Dogel), Tomsk (Burzhinsky), Moscow (Chervinsky) are not rich in students; the first and the last one by its nature is experimental and physiological, the second is experimental with a wedge, a bias ^ F. is studied at a crust, time in Western Europe in special pharmacol. in-takh at high fur boots. Pharmacol is perfectly arranged and equipped. in-you in Freiburg (Baden), Munich, Bonn, Dusseldorf. Nek-rye occupy separate buildings of 3-4 floors. In in-takh there are departments: experimental-vivisection, chemical, in some places bacteriological; library, museum, material, photographic laboratory; auditorium, separate rooms for the work of the professor, assistants and medical specialists; in some institutes there are rooms for practical training of students, a room for experimental animals, a room with a reduced temperature. The vivarium is set up at the institute in a special room with compartments for various animals; ranarius; glacier, basement. There is pharmacol in Italy. experimental in-you, but there are in-you of the mixed type-in-you F. with toxicology and in-you of pharmacology with pharmacognostic (Materia medica). In America, pharmacol. departments, laboratories, departments Materia medica and Therapeutics. Japan in all high fur boots has special pharmacol. in-you of the German type. In the USSR, pharmacol. ints are placed in the same building with in-tas of other departments. Ying-you and laboratories have demonstration collections of pharmacol. and pharmacological material, figures and tables prepared in accordance with the course read. Older institutes and laboratories have their own libraries. In the USSR, pharmacologists are not united into a separate society, but are members of the Union Society of Physiologists, Biochemists, Pharmacologists and Histologists, in whose congresses they take part, forming a separate section. Pharmacologists of the USSR also take part in the regional congresses of physiologists, pharmacologists and biologists, convened in Po-voll and very regularly in the south in the republics of the Transcaucasus and the Caucasus; the last congress was in Erivan in October 1934. Soviet pharmacologists do not have a separate printed organ; in fiziol. the journal of the USSR im. Sechenov Pharmacology has its own department. Teaching F. has developed in most countries under the predominant influence of the German school and consists of a lecture course, accompanied by a demonstration of the effect of drugs on animals (Austria, Switzerland, Poland, Czechoslovakia, Norway, the Baltic states, partly Italy, Japan); in other countries, the French wedge system is practiced, the study of medicines; England, "Italy and America switched to a mixed system of laboratory-clinical. Method. The USSR follows the model of the German school. Teaching experimental Ph, we began in the sixties with the course of Sokolovsky in Kazan. medical literature "in accordance with the pharmacognostic ^ therapy, the content of collections on Materia medica and consisted in the description of drugs from the pharmacognostic side and indication of their therapeutic use. According to the university charter of 1863, two departments were created at the medical faculties instead of one: one - "Pharmacognosy and Pharmacy", another - "Theoretical and Experimental Pharmacology." 2nd year 6 hours a week for two semesters, and F. in the 3rd year 6 hours a week, also for two semesters. method with demonstrations of experiments and preparations during the lecture. Practical exercises in F. were organized in exceptional cases (Likhachev, Boldyrev, Nikolaev). During the reorganization of all teaching in the USSR, the Department of Pharmacy and Pharmacognosy in 1923 was on honey. faculties were liquidated, and the department of F. was charged with the responsibility to include information on pharmacognosy and pharmacy in the course of F. with a recipe. chemistry, necessary for the assimilation of F. and the skillful disposal of drugs. F. was given 5 hours a week for teaching in both semesters in the third year. Compulsory practical lessons were introduced in 1926. Since the fall of 1934, F. has been allocated 150 hours for the third year in two semesters; according to the new plan, another 22 hours were added, which should be considered sufficient for teaching F. The introduction of compulsory for students practical classes in F., teaching it in our country compares favorably with foreign. Lit .: B about l dbfp ev V., A short guide for practical training in pharmacology, Kazan, 1913; Vershinin N., Pharmacology as the basis of therapy, Tomsk, 1933; Garkavi-Dandau D., A Brief Guide to Experimental Pharmacology, Baku, 1927; Tsramepitsky M., General Pharmacology, L.-M., 1931; about N e, Textbook of pharmacology, L.-M., 1935; Keshn and A., Guide to pharmacology, t. I-II, M., 1930-31; Kravkov N., Modern problems of pharmacology and materialism, St. Petersburg, 1903; he, Fundamentals of Pharmacology, parts 1-2, D.-M., 1933; Lavrov D., Fundamentals of Pharmacology and Toxicology, Odessa, 1923; Lyuba Shin A., Skvortsov V., Sobolev M. and Shishov I., Manual for practical exercises in pharmacology with toxicology, M., 1933; Müller F., Theoretical and clinical pharmacology, Berlin, 1921; Pravdiv N., Experienced introduction to the study of pharmacology, M., 1926; Skvortsov V., Textbook of pharmacology, M.-L., 1933; Soeshestskiy N., Course of pharmacology and pharmacotherapy of domestic animals, hours 1-2, M.-L., 1930-31; Tif-no M., Pharmacological reviews, collection of articles. 1-Pharmacology for 1928-29, M., 1932; Frobner E., Guide to pharmacology, M., 1934; Handbuch der experimentellen Pharmakologie, hrsg. v. A. Heffter u. W. Heubner, B. I-III, B. 1923-29 (lit.); H a n d about at 8 k at R., Pharmakologie in ihrer modernen Problemstellungen, Dresden-Jjpz., 1931; Magnus It., Einfaches pharmakologisches Praktikum f. Medizlner, B., 1921; Meyer H. u. G o t-t li e b R., Experimented Pharmakologie, B. - Wien, 1925 (Russian ed. St. Petersburg, 1913); Poulsson E., Lehrbuch der Pharmakologie, Lpz., 1920; Tap peiner H. u. Schmie-deberg 0., Grundriss der Pharmakologie, Lpz., 1909. Periodicals, -Russian Physiological Journal. Sechenov, L., since 1917; Archives internationa-les de pharmacodynamie, P., from 1898; Archiv fur experi-mcntelle Pathologie und Pharmakologie, Lpz., From 1873; Bericnte iiber die gesamte Physiologie und experimentelle Pharmakologie, B., from 1920; Japanese journal ol medical sciences, Tokyo, since 1922; Journal of pharmacology and experimental therapeutics, Baltimore, from 1909. See also lit. to Art. Physiology. V. Nikolaev.

1. The concept of treatment as directed correction of physiological disorders in the body. The benefits and risks of using medications. The grounds for their application. Safety assessment.

Pharmacology- the theoretical basis of pharmacotherapy.

Reasons for using drugs:

1) to correct and eliminate the cause of the disease

2) in case of insufficient preventive measures

3) for health reasons

4) obvious need based on level of knowledge and experience

5) striving to improve the quality of life

Benefits in prescribing medications:

1) correction or elimination of the cause of the disease

2) relief of symptoms of the disease if it is impossible to treat it

3) substitution of medicinal substances for natural biologically active substances, not produced by organisms in sufficient quantities

4) implementation of disease prevention (vaccines, etc.)

Risk- the likelihood that harm or damage will result from exposure; is equal to the ratio of the number of adverse (aversive) events to the size of the risk group.

A) unacceptable (harm> benefit)

B) acceptable (benefit> harm)

B) insignificant (105 - security level)

D) conscious

Drug safety assessment begins at the level of chemical laboratories synthesizing drugs. The preclinical assessment of drug safety is carried out by the Ministry of Health, FDA, etc. If the drug successfully passes this stage, its clinical assessment begins, consisting of four phases: Phase I - assessment of tolerance on healthy volunteers 20-25 years old, Phase II - on sick volunteers numbering less than 100 people suffering from a certain disease, phase III - multicenter clinical trials on large groups of people (up to 1000 people), phase IV - monitoring the drug for 5 years after its official approval. If a drug successfully passes all of these phases, it is considered safe.

2. The essence of pharmacology as a science. Sections and fields of modern pharmacology. The main terms and concepts of pharmacology are pharmacological activity, action, effectiveness of chemicals.

Pharmacology- the science of medicines in all aspects - the theoretical basis of therapy:

A) the science of the interaction of chemicals with living systems

B) the science of managing the vital processes of the body with the help of chemicals.

Sections of modern pharmacology:

1) Pharmacodynamics- studies a) the effect of drugs on the human body, b) the interaction of various drugs in the body while prescribing them, c) the effect of age and various diseases on the effect of drugs

2) Pharmacokinetics- studies the absorption, distribution, metabolism and excretion of drugs (i.e., how the patient's body reacts to drugs)

3) Pharmacogenetics- studies the role of genetic factors in the formation of the body's pharmacological response to drugs

4) Pharmacoeconomics- evaluates the results of use and the cost of drugs for making a decision on their subsequent practical use

5) Pharmacoepidemiology- studies the use of drugs and their effects at the level of populations or large groups of people to ensure the use of the most effective and safe drugs

Pharmacological (biological) activity- the property of a substance to cause changes in the biosystem (human body). Pharmacological substances = biologically active substances (BAS)

pharmachologic effect- the influence of drugs on the object and its targets

Pharmacological effect- the result of the action of a substance in the body (modification of physiological, biochemical processes, morphological structures) - a quantitative, but not qualitative change in the state of biosystems (cells, tissues, organs).

The effectiveness of drugs- the ability of drugs to cause certain pharmacological effects necessary in this case in the body. Assessed on the basis of "substantial evidence" - adequate well-controlled studies and clinical trials conducted by experts with appropriate scientific training and experience in drug research of this type (FDA)

3. The chemical nature of drugs. Factors providing the therapeutic effect of drugs are pharmacological action and placebo effects.

There are drugs 1) vegetable 2) animal 3) microbial 4) mineral 5) synthetic

Synthetic drugs are represented by almost all classes of chemical compounds.

pharmachologic effect- the influence of drugs on the object and its target.

Placebo- any component of therapy that does not have any specific biological effect on the disease being the object of treatment.

It is used for the purpose of control in assessing the effect of drugs and in order to benefit the patient without any pharmacological agents as a result of only psychological influence (i.e. Placebo effect).

All types of treatment have a psychological component, or a satisfying one ( Placebo effect) or disturbing ( Nocebo effect). An example of a placebo effect: a rapid improvement in a patient with a viral infection when using antibiotics that do not affect viruses.

The benefit of the placebo effect is related to the psychological impact on the patient. It will be maximum only when using it. Combined with treatment methods that have a pronounced specific effect. Expensive substances as a placebo also help to achieve a greater response.

Indications for placebo use:

1) weak mental disorders

2) psychological support for a patient with an incurable chronic disease or suspected of having a difficult diagnosis

4. Sources and stages of drug creation. Definition of the concepts of medicinal substance, medicinal product, medicinal product and dosage form. The name of the drugs.

Sources of drug creation:

A) natural raw materials: plants, animals, minerals, etc. (cardiac glycosides, pork insulin)

B) modified natural biologically active substances

B) synthetic compounds

D) genetic engineering products (recombinant insulin, interferons)

Stages of drug creation:

1. Synthesis of drugs in a chemical laboratory

2. Preclinical assessment of the activity and undesirable effects of drugs of the Ministry of Health and other organisms

3. Clinical trials of drugs (for more details see section 1)

Medicine- any substance or product used to modify or investigate physiological systems or pathological conditions for the benefit of the recipient (according to WHO, 1966); individual substances, mixtures of substances or compositions of unknown composition with proven medicinal properties.

Medicinal substance- an individual chemical compound used as a medicine.

Dosage form- a convenient form for practical use, given to a drug to obtain the required therapeutic or prophylactic effect.

Medicinal product- a medicinal product in a specific dosage form, approved by a government authority.

5. Routes of drug administration into the body and their characteristics. Presystemic elimination of drugs.

1. For systemic action

A. Enteral route of administration: oral, sublingual, buccal, rectal, tube

B. Parenteral route of administration: intravenous, subcutaneous, intramuscular, inhalation, subarachnoid, transdermal

2. For local exposure: cutaneous (epicutary), on mucous membranes, in the cavity (abdominal, pleural, articular), in tissue (infiltration)

Route of drug administration

Dignity

disadvantages

Orally - by mouth

1. Convenient and easy for the patient

2. Sterility of drugs is not required

1. The absorption of many drugs depends on food intake, the functional state of the gastrointestinal tract and other factors that are hardly taken into account in practice

2. Not all drugs are well absorbed in the digestive tract

3. Some drugs are destroyed in the stomach (insulin, penicillin)

4. Part of the drug has NLR on the gastrointestinal mucosa (NSAIDs - mucosal manifestations, antacids - suppress motor skills)

5. Not applicable for patients in an unconscious state and with impaired swallowing

Sublingual and buccal

1. Convenient and quick introduction

2. Fast absorption of drugs

3. Medicines are not subject to presystemic elimination

4. The action of the drug can be quickly interrupted

1. Inconvenience caused by frequent regular use of pills

2. Irritation of the oral mucosa, excessive salivation, facilitating the swallowing of drugs and reducing its effectiveness

3. Bad taste

Rectally

1. Half of the drugs are not subject to presystemic metabolism

2. The gastrointestinal mucosa is not irritated

3. Convenient when other routes of administration are unacceptable (vomiting, motion sickness, infants)

4. Local action

1. Unpleasant psychological moments for the patient

2. The absorption of drugs is significantly slowed down when the rectum is not emptied.

Intravascular (usually intravenous

1. Rapid entry into the bloodstream (emergency conditions)

2. Rapid creation of high systemic concentration and the ability to manage it

3. Allows the introduction of drugs that are destroyed in the gastrointestinal tract

1. Technical difficulties of intravascular access

2. Risk of infection at the injection site

3. Vein thrombosis at the injection site of drugs (erythromycin) and pain (potassium chloride)

4. Some drugs are adsorbed on the walls of droppers (insulin)

Intramuscularly

Sufficiently fast absorption of the drug into the blood (10-30 min)

Risk of local complications

Subcutaneously

1. The patient can inject independently after training.

2. Long-term effect of drugs

1. Slow absorption and manifestation of the drug effect

2. Atrophy of adipose tissue at the injection site and a decrease in the rate of absorption of drugs

Inhalation

1. Rapid onset of action and high concentration at the injection site in the treatment of respiratory diseases. ways

2. Good controllability of the action

3. Reduction of toxic systemic effects

1. The need for a special device (inhaler)

2. Difficulty using pressurized aerosols for some patients

Local PM

1. High effective concentration of drugs at the injection site

2. Undesirable systemic effects of this drug are avoided

If the integrity of the skin is violated, the drug can enter the systemic circulation - a manifestation of undesirable systemic effects.

Presystemic elimination of drugs (first pass effect)- the process of biotransformation of the drug before the drug enters the systemic circulation. Enzymatic systems of the intestine, portal vein blood and hepatocytes are involved in presystemic elimination with oral administration of the drug.

When administered intravenously, there is no presystemic elimination.

In order for an orally taken drug to have a beneficial effect, it is necessary to increase its dose to compensate for losses.

6. Transport of drugs across biological barriers and its varieties. The main factors affecting the transport of drugs in the body.

Ways of absorption (transport) of drugs through biological membranes:

1) Filtration (water diffusion) - passive movement of substance molecules along a concentration gradient through pores filled with water in the membrane of each cell and between neighboring cells, typical for water, some ions, small hydrophilic molecules (urea).

2) Passive diffusion (lipid diffusion) is the main mechanism of drug transfer, the process of drug dissolution in membrane lipids and movement through them.

3) Transport by means of specific carriers - drug transfer by means of carriers built into the membrane (usually proteins) is characteristic of hydrophilic polar molecules, a number of inorganic ions, sugars, amino acids, pyrimidines:

a) facilitated diffusion - carried out along the concentration gradient without the consumption of ATP

b) active transport - against the concentration gradient with the costs of ATP

Saturable process - that is, the rate of absorption increases only until the number of drug molecules becomes equal to the number of carriers.

4) Endocytosis and pinocytosis - the drug binds to a special recognizing component of the cell membrane, membrane invagination occurs and a vesicle is formed containing drug molecules. Subsequently, the drug is released from the vesicle into the cell or transported out of the cell. Typical for high molecular weight polypeptides.

Factors affecting the transport of drugs in the body:

1) physical and chemical properties of the substance (hydro- and lipophilicity, ionization, polarizability, molecular size, concentration)

2) structure of transfer barriers

3) blood flow

7. Transport through membranes of medicinal substances with variable ionization (Henderson-Hasselbalch ionization equation). Transfer control principles.

All drugs are weak acids or weak bases, which have their own values ​​of the ionization constant (pK). If the pH value of the medium is equal to the pK value of the drug, then 50% of its molecules will be in the ionized state and 50% in the non-ionized state, and the medium for the drug will be neutral.

In an acidic medium (pH less than pK), where there is an excess of protons, the weak acid will be in the undissociated form (R-COOH), i.e., it will be bound with a proton - protonated. This form of acid is uncharged and readily soluble in lipids. If the pH is shifted to the alkaline side (i.e., the pH becomes greater than pK), then the acid will begin to dissociate and lose a proton, passing into a non-protonated form, which has a charge and is poorly soluble in lipids.

In an alkaline medium, where there is a deficiency of protons, the weak base will be in the undissociated form (R-NH2), that is, it will be unprotonated and devoid of charge. This form of the base is highly lipid soluble and rapidly absorbed. In an acidic medium, there is an excess of protons and the weak base will begin to dissociate, while binding the protons and forming the protonated, charged form of the base. This form is poorly soluble in lipids and poorly absorbed.

Hence, The absorption of weak acids takes place mainly in an acidic medium, and of weak bases in an alkaline medium.

Features of the metabolism of weak acids (SC):

1) stomach: SA in the acidic contents of the stomach is not ionized, and in the alkaline medium of the small intestine it will dissociate and the SA molecules will acquire a charge. Therefore, absorption of weak acids will be most intense in the stomach.

2) in the blood, the medium is sufficiently alkaline and the absorbed SC molecules will transform into an ionized form. The renal glomerulus filter allows both ionized and non-ionized molecules to pass through, therefore, despite the charge of the molecule, SC will be excreted into the primary urine

3) if the urine is alkaline, then the acid will remain in an ionized form, will not be able to be reabsorbed back into the bloodstream and will be excreted in the urine; If urine is acidic, then the drug will go into a non-ionized form, which is easily reabsorbed back into the blood.

Features of the metabolism of weak bases: opposite to SC (absorption is better in the intestine; in alkaline urine they are reabsorbed)

That., To accelerate the elimination of a weak acid from the body, urine must be alkalized, and in order to accelerate the elimination of a weak base, it must be acidified (detoxification according to Popov).

The quantitative dependence of the drug ionization process at various pH values ​​of the medium makes it possible to obtain the equation HendersonHasselbach:

Where pKa corresponds to the pH value at which the concentrations of the ionized and non-ionized forms are in equilibrium .

The Henderson-Hasselbach equation makes it possible to estimate the degree of drug ionization at a given pH value and to predict the probability of its penetration through the cell membrane.

(1)For dilute acid, A,

HA ↔ H + + A -, where HA is the concentration of the non-ionized (protonated) form of the acid and A - is the concentration of the ionized (non-protonated) form.

(2) For weak base, B,

BH + ↔ H + + B, where BH + is the concentration of the protonated form of the base, B is the concentration of the non-protonated form

Knowing the pH of the medium and the pKa of the substance, it is possible to determine the degree of drug ionization by the calculated logarithm, and hence the degree of its absorption from the gastrointestinal tract, reabsorption or excretion by the kidneys at different pH values ​​of urine, etc.

8. Transfer of drugs in the body. Water diffusion and diffusion in lipids (Fick's law). Active transport.

The transfer of drugs in the body can be carried out by water and lipid diffusion, active transport, endo - and pinocytosis.

Features of the transfer of drugs in the body by water diffusion:

1. Epithelial integuments (mucous membranes of the gastrointestinal tract, oral cavity, etc.) - water diffusion of only very small molecules (methanol, lithium ions, etc.)

2. Capillaries (except for cerebral ones) - filtration of substances with a molecular weight of up to 20-30 thousand. Yes.

3. Capillaries of the brain - basically do not have water pores, with the exception of the areas of the pituitary gland, pineal gland, zone IV ventricle, choroid plexus, median eminence

4. Placenta - has no water pores (although the issue is controversial).

5. Binding of drugs to blood proteins prevents their exit from the bloodstream, and hence water diffusion

6. Diffusion in water depends on the size of drug molecules and water pores

Features of lipid diffusion:

1. The main mechanism of drug transfer across cell membranes

2. Determined by the lipophilicity of the diffusible substance (ie, the "oil / water" distribution coefficient) and the concentration gradient, it can be limited by the very low solubility of the substance in water (which prevents the drug from penetrating into the aqueous phase of membranes)

3. Non-polar compounds diffuse easily, ions are difficult to diffuse.

Any diffusion (both water and lipids) obeys Fick's law of diffusion:

Diffusion rate - the number of drug molecules carried per unit time; C1 is the concentration of the substance outside the membrane; C2 is the concentration of the substance from the inside of the membrane.

Corollary from Fick's law:

1) the filtration of the drug is the higher, the greater its concentration at the injection site (S of the absorbed surface in the intestine is greater than in the stomach, therefore the absorption of the drug into the intestine is faster)

2) the higher the drug concentration at the injection site, the higher the drug filtration

3) the filtration of drugs is the higher, the less the thickness of the biological membrane to be overcome (the thickness of the barrier in the alveoli of the lungs is much less than that of the skin, therefore the absorption rate is higher in the lungs)

Active transport- transfer of drugs, regardless of the concentration gradient using the energy of ATP, is characteristic of hydrophilic polar molecules, a number of inorganic ions, sugars, amino acids, pyrimidines. Characterized by: a) selectivity for certain compounds b) the possibility of competition of two substances for one transport mechanism c) saturation at high concentrations of the substance d) the possibility of transport against the concentration gradient e) energy consumption.

9. The central postulate of pharmacokinetics is the concentration of a drug in the blood - the main parameter for controlling the therapeutic effect. Problems solved on the basis of knowledge of this postulate.

The central postulate (dogma) of pharmacokinetics: the concentration of drugs in blood plasma determines (quantitatively determines) the pharmacological effect.

In most cases, the rate of absorption, distribution, metabolism and excretion of drugs is proportional to their concentration in blood plasma (obeys the law of mass action), therefore, knowing it is possible:

1) determine the half-life (for drugs with first-order kinetics)

2) explain the duration of some toxic effects of drugs (for drugs in high doses with saturation kinetics)

10. Bioavailability of drugs - definition, essence, quantitative expression, determinants. Bioavailability

Bioavailability (F) - characterizes the completeness and rate of absorption of drugs with extra-systemic routes of administration - reflects the amount of unchanged substance that has reached the systemic circulation, relative to the initial dose of the drug.

F is 100% for drugs that are administered intravenously. When administered by other routes, F is usually less due to incomplete absorption and partial metabolism in peripheral tissues. F is 0 if the drug is not absorbed from the lumen of the gastrointestinal tract.

To estimate F, a curve is plotted as a function of the drug concentration in the blood versus time after its intravenous administration, as well as after administration by the investigated route. This is the so-called. pharmacokinetic curves of the relationship "time-concentration". The area under the pharmacokinetic curve is found by integration and F is calculated as the ratio:

≤ 1, where AUC is the Area Under Curve

Bioavailability> 70% is considered high, below 30% - low.

Determinants of bioavailability:

1) suction speed

2) completeness of absorption - insufficient absorption of drugs due to its very high hydrophilicity or lipophilicity, metabolism by intestinal bacteria when administered enterally, etc.

3) presystemic elimination - with high biotransformation in the liver F drugs are low (nitroglycerin when administered orally).

4) dosage form - sublingual tablets and rectal suppositories help drugs to avoid presystemic elimination.

11. Distribution of drugs in the body. Compartments, ligands. Main determinants of distribution.

Distribution Drugs - the process of spreading drugs through organs and tissues after they enter the systemic circulation.

Distribution bays:

1. Extracellular space (plasma, intercellular fluid)

2. Cells (cytoplasm, membrane of organelles)

3. Adipose and bone tissue (deposition of drugs)

In a person weighing 70 kg, the volume of liquid media is 42 liters in total, then if:

[Vd = 3-4 L, then all the medicine is distributed in the blood;

[Vd = 4-14 L, then all the drug is distributed in the extracellular fluid;

[Vd = 14-42 l, then all the drug is approximately evenly distributed in the body;

[Vd> 42 L, then all the drug is located mainly in the extracellular space.

Molecular ligands of drugs:

A) specific and non-specific receptors

B) blood proteins (albumin, glycoprotein) and tissues

C) connective tissue polysaccharides

D) nucleoproteins (DNA, RNA)

Distribution determinants:

· The nature of drugs- the smaller the size of the molecule and the more lipophilic the drug, the faster and more uniform its distribution.

· Organ size- the larger the organ, the more drug can enter it without a significant change in the concentration gradient

· Organ blood flow- in well perfused tissues (brain, heart, kidneys), the therapeutic concentration of the substance is created much earlier than in poorly perfused tissues (fatty, bone)

· The presence of histohematogenous barriers- drugs easily penetrate tissues with poorly expressed GHB

· Plasma protein binding- the larger the bound drug fraction, the worse its distribution in the tissue, since only free molecules can leave the capillary.

· Deposition of the drug in tissues- the binding of drugs to tissue proteins contributes to its accumulation in them, since the concentration of free drugs in the perivascular space decreases and a high concentration gradient between blood and tissues is constantly maintained.

A quantitative characteristic of drug distribution is the apparent volume of distribution (Vd).

Apparent volume of distributionVd Is a hypothetical volume of fluid in which the entire administered dose of the drug can be distributed in order to create a concentration equal to the concentration in the blood plasma.

Vd is equal to the ratio of the administered dose (the total amount of the drug in the body) to its concentration in the blood plasma:

.

The larger the apparent volume of distribution, the more drugs are distributed into the tissue.

12. Elimination constant, its essence, dimension, relationship with other pharmacokinetic parameters.

Elimination rate constant(kel, min-1) - shows what part of drugs is eliminated from the body per unit of time Þ Kel = Avid / Atot, where Avid is the amount of drugs released in units. time, Absh - the total amount of drugs in the body.

The kel value is usually found by solving a pharmacokinetic equation describing the process of drug elimination from the blood; therefore, kel is called a model kinetic index. Kel is not directly related to the planning of the dosage regimen, but its value is used to calculate other pharmacokinetic parameters.

The elimination constant is directly proportional to the clearance and inversely proportional to the volume of distribution (from the definition of clearance): Kel = CL / Vd; = hour-1 / min-1 = fraction per hour.

13. The half-life of drugs, its essence, dimension, relationship with other pharmacokinetic parameters.

Half-elimination period(t½, min) is the time required to reduce the concentration of drugs in the blood by exactly half. In this case, it does not matter in what way a decrease in concentration is achieved - with the help of biotransformation, excretion, or due to a combination of both processes.

The half-life is determined by the formula:

The half-life is the most important pharmacokinetic parameter that allows:

B) determine the time of complete elimination of the drug

C) predict the concentration of drugs at any time (for drugs with first-order kinetics)

14. Clearance as the main pharmacokinetic parameter for dosing regimen management. Its essence, dimension and relationship with other pharmacokinetic parameters.

Clearance(Cl, ml / min) - the volume of blood that is cleared from drugs per unit of time.

Since plasma (blood) is the "visible" part of the volume of distribution, the clearance is the fraction of the volume of distribution from which the drug is released per unit of time. If we denote the total amount of the drug in the body through General, and the amount that was allocated after Avyd, then:

On the other hand, it follows from the definition of the volume of distribution that the total amount of the drug in the body is Absh =Vd´ CTer / plasma... Substituting this value into the clearance formula, we get:

.

Thus, clearance is the ratio of the rate of elimination of a drug to its concentration in blood plasma.

In this form, the clearance formula is used to calculate the maintenance dose of the drug ( DNS), i.e. the dose of the drug that should compensate for the loss of the drug and maintain its level at a constant level:

Injection rate = Excretion rate =Cl´ CTer(dose / min)

DNS= injection rate´ T (T- the interval between taking the medication)

Ground clearance is additive, i.e., the elimination of a substance from the body can occur with the participation of processes in the kidneys, lungs, liver and other organs: Clsystem = Clrenal. + Cl liver + Cld.

Clearance bound With drug half-life and volume of distribution: t1 / 2 = 0.7 * Vd / Cl.

15. Dose. Types of doses. Drug dosage units. The goals of drug dosing, methods and options for administration, the interval of administration.

The effect of drugs on the body is largely determined by their dose.

Dose- the amount of a substance introduced into the body at one time; expressed in weight, volume or conventional (biological) units.

Dose types:

A) single dose - the amount of substance per dose

B) daily dose - the amount of the drug prescribed for a day in one or more doses

C) course dose - the total amount of the drug for the course of treatment

D) therapeutic doses - doses in which the drug is used for therapeutic or prophylactic purposes (threshold, or minimum effective, average therapeutic and higher therapeutic doses).

E) toxic and lethal doses - doses of drugs at which they begin to have pronounced toxic effects or cause death of the body.

E) loading (introductory) dose - the number of injected drugs, which fills the entire volume of distribution of the body in the effective (therapeutic) concentration: VD = (Css * Vd) / F

G) maintenance dose - a systematically administered amount of drugs, which compensates for the loss of drugs with clearance: PD = (Css * Cl * DT) / F

Pharmaceutical dosage units:

1) in grams or fractions of a gram of drugs

2) the number of drugs per 1 Kg body weight (for example, 1 Mg / kg) or per unit surface area of ​​the body (for example, 1 Mg / m2)

Drug dosing goals:

1) determine the amount of drugs required in order to cause the desired therapeutic effect with a certain duration

2) avoid the phenomena of intoxication and side effects with the introduction of drugs

Methods of drug administration: 1) enteral 2) parenteral (see section 5)

Drug administration options:

A) continuous (by long-term intravascular infusion of drugs by drop or through automatic dispensers). With continuous administration of drugs, its concentration in the body changes smoothly and does not undergo significant fluctuations.

B) intermittent administration (by injection or non-injection methods) - administration of a drug at regular intervals (dosing intervals). With intermittent administration of drugs, its concentration in the body constantly fluctuates. After taking a certain dose, it first rises, and then gradually decreases, reaching minimum values ​​before the next administration of the drug. Fluctuations in concentration are the more significant, the larger the administered dose of the drug and the interval between injections.

Injection interval- the interval between the administered doses, ensuring the maintenance of the therapeutic concentration of the substance in the blood.

16. Administration of drugs at a constant rate. Kinetics of drug concentration in blood. Stationary concentration of the drug in the blood ( Css), time of its achievement, calculation and management of it.

The peculiarity of the introduction of drugs at a constant rate is a smooth change in its concentration in the blood upon administration, while:

1) the time to reach a steady-state drug concentration is 4-5t½ and does not depend on the infusion rate (the size of the administered dose)

2) with an increase in the infusion rate (injected dose), the СSS value also increases in a proportional number of times

3) elimination of the drug from the body after the termination of the infusion takes 4-5t½.

WITHSs- equilibrium stationary concentration- the concentration of drugs achieved at the rate of administration equal to the rate of excretion, therefore:

(from the definition of clearance)

For each subsequent half-life, the drug concentration increases by half of the remaining concentration. All drugs that obey the first order elimination law are Will reachCssafter 4-5 half-lives.

Level C Management ApproachesSs: change the administered drug dose or the interval of administration

17. Intermittent administration of drugs. Kinetics of drug concentration in blood, therapeutic and toxic concentration range. Calculation of the stationary concentration ( CSs), the boundaries of its oscillations and its control. Adequate discrete dosing interval.

Fluctuations in the concentration of drugs in blood plasma: 1 - with constant intravenous drip; 2 - with a fractional introduction of the same daily dose with an interval of 8 hours; 3 - with the introduction of a daily dose with an interval of 24 hours.

Intermittent drug administration- the introduction of a certain amount of drugs at intervals.

The steady-state equilibrium concentration is achieved after 4-5 half-elimination periods, the time to reach it does not depend on the dose (at the beginning, when the drug concentration level is low, the rate of its elimination is also low; as the amount of the substance in the body increases, the rate of its elimination also increases, therefore, early or late a moment will come when the increased rate of elimination will balance the administered drug dose and further increase in concentration will stop)

Css is directly proportional to the drug dose and inversely proportional to the injection interval and drug clearance.

Css Swing Boundaries: ; Cssmin = Cssmax × (1 - email). Fluctuations in drug concentration are proportional to T / t1 / 2.

Therapeutic range (safety corridor, therapy window)- This is the range of concentrations from the minimum therapeutic to causing the first signs of side effects.

Toxic range- concentration range from the highest therapeutic to lethal.

Adequate administration of discrete doses: a mode of administration in which the fluctuation of the drug concentration in the blood falls within the therapeutic range. To determine an adequate regimen of drug administration, it is necessary to calculate. The difference between Cssmax and Cssmin should not exceed 2Css.

Oscillation controlCss:

Swing rangeCssdirectly proportional to the dose of drugs and inversely proportional to the interval of its administration.

1. Change the dose of drugs: with an increase in the dose of a drug, the range of fluctuations of its Css proportionally increases

2. Change the interval of drug administration: with an increase in the interval of drug administration, the range of fluctuations of its Css proportionally decreases

3. Simultaneously change the dose and the interval of administration

18. Introductory (loading) dose. Therapeutic meaning, calculation by pharmacokinetic parameters, conditions and limitations of its use.

Introductory (loading) dose- a dose administered at one time and filling the entire volume of distribution in the current therapeutic concentration. VD = (Css * Vd) / F; = mg / l, = l / kg

Therapeutic meaning: the introductory dose quickly provides an effective therapeutic concentration of drugs in the blood, which makes it possible, for example, to quickly stop an attack of asthma, arrhythmias, etc.

An introductory dose can be administered at a time only when The process of substance distribution is ignored

Limiting the use of VD: if the drug is distributed Significantly slower than its entry into the bloodstream, the introduction of the entire loading dose at once (especially intravenously) will create a concentration significantly higher than the therapeutic one and will cause the occurrence of toxic effects. VD use condition: therefore, the introduction of loading doses Should always be slow or fractional.

19. Maintenance doses, their therapeutic meaning and calculation for the optimal dosage regimen.

Maintenance dose- the dose of drugs administered systematically, which fills the clearance volume, i.e., the Vd fragment that is cleared of drugs during the DT interval: PD = (Css * Cl * DT) / F.

Therapeutic meaning: PD compensates for losses with clearance over the interval between drug injections.

Calculation for optimal dosage of drugs (for quick relief of an attack):

1. Calculate VD: VD = (Css * Vd) / F

2. Select the DT injection interval (usually most drugs are prescribed with an interval close to t1 / 2) and calculate the AP: AP = (Css * Cl * DT) / F

3. Check if the drug fluctuations in the blood go beyond the therapeutic range by calculating Cssmax and Cssmin: ; Cssmin = Cssmax × (1 - email). The difference between Cssmax and Cssmin should not exceed two Css.

The fraction to be eliminated is found according to the graph (see section 16) or according to the formula:

4. If, at the interval of drug administration we have chosen, its fluctuations go beyond the therapeutic range, change DT and repeat the calculation (point 2 - point 4)

NB! If the drug is not intended for the relief of emergency conditions or is taken in pills, the VD is not calculated.

20. Individual, age and sex differences in drug pharmacokinetics. Corrections for the calculation of individual values ​​for the volume of distribution of drugs.

1. Age differences in the pharmacokinetics of drugs.

1. The stratum corneum is thinner, therefore, when applied to the skin, drugs are better absorbed. The absorption of drugs by rectal administration is also better.

2. The volume of fluid in the body of children is 70-80%, while in adults it is only »60%, therefore, the Vd of hydrophilic drugs they have is higher and higher doses are required.

3. In a newborn, the level of albumin in plasma is lower than in adults, therefore, the binding of drugs to protein is less intense in them.

4. Newborns have low intensity of cytochrome P450 systems and conjugating enzymes, but high activity of methylating systems.

5. The rate of glomerular filtration in the kidneys of children under 6 months is 30-40% of the rate of adults, therefore, renal excretion of drugs is reduced.

1. There is a decrease in the concentration of albumin in the blood plasma and the fraction of the drug associated with the protein

2. The water content in the body decreases from 60% to 45%, therefore, the accumulation of lipophilic drugs increases.

3. The glomerular filtration rate can drop up to 50-60% of the rate of a mature patient, therefore renal elimination of drugs is sharply limited.

2. Sex differences in the action of drugs... For women, less body weight is characteristic than for men, therefore, the size of the drug doses for them should, as a rule, be at the lower limit of the range of therapeutic doses.

3. Pathological conditions of the body and the effect of drugs

A) liver diseases: F drugs due to the shutdown of the first-pass metabolism, a fraction of unbound drugs due to a lack of albumin synthesis, the effects of drugs are prolonged due to their biotransformation.

B) kidney pathology: the elimination of drugs that are excreted through the kidneys slows down

4. Genetic factors- a deficiency of certain enzymes of drug metabolism can contribute to the prolongation of their action (pseudocholinesterase, etc.)

Corrections for calculating individual values ​​of the volume of distribution of drugs:

A) for obesity, lipophobic drugs are insoluble in adipose tissue Þ it is necessary to calculate the ideal weight by height (Broca's formula: ideal weight = height (in cm) - 100) and recalculate Vd by the ideal weight by height.

B) in case of edema, you need to calculate the excess volume of water = excess weight - ideal, Vd should be increased by a liter of each excess kilogram of water.

Dependence of the main pharmacokinetic parameters on various factors:

1. Absorption of drugs: at age ¯ drug absorption, its metabolism in the course of presystemic elimination, the bioavailability of drugs changes.

2. Volume of distribution Vd: ¯ with age and with obesity, with edema

3. Half-life: changes with age and obesity (since Vd decreases)

4. Clearance: determined by the functional state of the kidneys and liver

21. Renal clearance of drugs, mechanisms, their quantitative and qualitative characteristics.

Renal clearance is a measure of the volume of blood plasma that is cleared of the drug from the drug per unit of time by the kidneys: Cl (ml / min) = U × V / P, where U is the concentration of drugs in ml of urine, V is the volume of urine excreted in min and P = drug concentration in ml of plasma.

Renal clearance mechanisms and their characteristics:

1. Filtration: Drugs emitted Filtration only(insulin) will have a clearance equal to GFR (125-130 ml / min)

Determined by: renal blood flow, unbound drug fraction and kidney filtration capacity.

Most drugs have low molecular weights and therefore freely filter from plasma in the glomerulus.

2. Active secretion: Drugs emitted Filtration and total secretion(paraaminogippuric acid), will have a clearance equal to renal plasma clearance (650 ml / min)

The renal tubule contains two transport systems that can separate drugs into an ultrafiltrate, one for organic acids and another for organic bases. These systems require energy to actively transport against the concentration gradient; they are a place of competition for a carrier of some drugs with others.

Determined by: maximum secretion rate, urine volume

3. Reabsorption: clearance values ​​between 130 and 650 ml / min suggest that the drug is Filtered, excreted, and partially reabsorbed

Reabsorption occurs throughout the entire renal canal and depends on the polarity of the drug, non-polar, lipophilic are reabsorbed.

Determined by: primary pH value and drug ionization

A number of indicators such as Age, joint use of several drugs, diseases significantly affect renal clearance:

A) renal failure ® decrease in drug clearance; high level of drugs in the blood

B) glomerulonephritis ® loss of serum protein, which was usually available and associated with drugs ® increase in the level of the free fraction of drugs in plasma

22. Factors affecting the renal clearance of drugs. Dependence of clearance on the physicochemical properties of drugs.

Factors affecting renalCl:

A) glomerular filtration

B) renal blood flow rate

B) maximum rate of secretion

D) urine volume

E) fraction unbound in blood

Dependence of renal clearance on the physicochemical properties of drugs:

General patterns: 1) polar drugs are not reabsorbed, non-polar drugs are reabsorbed 2) ionic drugs are secreted, non-ionic drugs are not secreted.

I. Non-polar non-ionic substances: filtered only in unbound forms, not secreted, reabsorbed

Renal clearance is small and is determined by: a) the fraction of drugs unbound in the blood b) the volume of urine

II. Polar non-ionic substances: filtered in unbound form, do not secrete, do not reabsorb

Renal clearance is high, determined by: a) the fraction of drugs unbound in the blood b) the rate of glomerular filtration

III. Non-polar ionized in urine in non-ionic form: filtered, actively secreted, non-polar reabsorbed

Renal clearance is determined by: a) the fraction of drugs unbound in the blood b) the fraction of drugs ionized in the urine c) the volume of urine

IV. Polar ionized in urine in non-ionized form: filtered, actively secreted, not reabsorbed

Renal clearance is determined by: a) renal blood flow and glomerular filtration rate b) maximum secretion rate

23. Hepatic drug clearance, its determinants and limitations. Enterohepatic drug cycle.

Mechanisms of hepatic clearance:

1) metabolism (biotransformation) by oxidation, reduction, alkylation, hydrolysis, conjugation, etc.

The main strategy of xenobiotic metabolism: non-polar substances ® polar (hydrophilic) metabolites excreted in the urine.

2) secretion (excretion of non-transformed substances into bile)

Only polar substances with a molecular weight> 250 active are transported into bile (organic acids, bases).

Determinants of hepatic clearance:

A) The rate of blood flow in the liver

B) Maximum rate of excretion or metabolic transformations

B) Km - Michaelis constant

D) Non-protein-bound fraction

Limitations of hepatic clearance:

1. If Vmax / Km is large → Cl pecs = blood flow velocity in the liver

2. If Vmax / Km mean values ​​→ Cl = the sum of all factors

3. If Vmax / Km is small → Cl furnace is small, limited

Enterohepatic drug cycle - A number of drugs and products of their transformation in significant quantities are excreted with bile into the intestines, from where they are partially excreted with excrement, and partly - Reabsorbed into the blood, again enters the liver and is excreted into the intestines.

Hepatic elimination of drugs can be significantly altered Liver disease, age, diet, genetics, duration of drug prescription(for example, due to the induction of hepatic enzymes), and other factors.

24. Factors that change the clearance of medicinal substances.

1. Drug interactions at the level of: renal secretion, biochemical transformation, phenomena of enzymatic induction

2. Kidney disease: blood flow disturbances, acute and chronic kidney damage, outcomes of long-term renal disease

3. Liver diseases: alcoholic cirrhosis, primary cirrhosis, hepatitis, hepatomas

4. Diseases of the gastrointestinal tract and endocrine organs

5. Individual intolerance (lack of acetylation enzymes - aspirin intolerance)

25. Correction of drug therapy for liver and kidney diseases. General approaches. Correction of the dosage regimen under the control of the total clearance of the drug.

1. Cancel drugs that are not necessary

2. For kidney disease, use drugs excreted in the liver and vice versa.

3. Reduce the dose or increase the interval between injections

4. Close monitoring of side effects and toxic effects

5. In the absence of a pharmacological effect, the dose must be increased slowly and under the control of pharmacological and toxic effects.

6. If possible, determine the concentration of the substance in the plasma and correct the drug Cl therapy individually

7. Use an indirect method of assessing Cl.

Correction of the dosage regimen under the control of the total clearance of the drug:

Dose adjustment : Dind = Dtyp. × Clind. / Cltyp.

With continuous intravenous administration of the drug: Individual rate of administration = Typical rate of administration × Cl ind. / Cl typical

With intermittent administration: 1) change the dose 2) change the interval 3) change both parameters. For example, if the clearance is reduced by 50%, you can reduce the dose by 50% and keep the interval, or double the interval and keep the dose. It is preferable to reduce the dose and maintain the interval of administration.

26. Correction of the dosage regimen under the control of the residual renal function.

Clearance of creatinine- the most important quantitative indicator of renal function, on the basis of which it is possible to adjust the dosage regimen

We know:

A) residual renal function, determined by creatinine clearance in a given patient Clcr / patient

B) the total clearance of a given drug (CLP / total) and the proportion of renal drug clearance in the total clearance

B) normal creatinine clearance Clcr / normogram

3) Css and F for this LAN (from the reference)

Find: drug dose for this patient

ClPP / renal rate = ClPP / total X share of renal drug clearance in the total clearance

Сlp / renal patient = Clcr / patient / Сlcr / norm * Clls / renal norm

ClPP / non-renal rate = ClPP / total - ClPP / renal rate

ClPS / general patient = CLPS / renal patient + ClPS / non-renal norm

The dose of this drug inside with normal renal function is: PD norm = Css X Cl / F

The dose of this drug inside for our patient is equal to: PD of the patient = PD norm X СlPS / general patient / СlPS / total

Answer: PDbolny

27. Correction of drug therapy for liver damage and other pathological conditions.

Liver disease can reduce clearance and lengthen the half-life of many drugs. However, in some drugs that are eliminated by the liver, these parameters do not change in case of liver dysfunction, therefore Liver disease does not always affect intrinsic hepatic clearance... There is currently no reliable marker that can be used to predict hepatic clearance similar to creatinine clearance.

For correction of the dosage regimen in case of kidney disease, see paragraph 26 above, for general principles of correction, see paragraph 25.

28. Strategy for individual drug therapy.

Recognition of the important role of concentration as a connecting link of pharmacokinetics and pharmacodynamics contributes to the creation of a target concentration strategy - to optimize the dose in a given patient based on measuring the drug concentration. It consists of the following stages:

1. Choice of target concentration

2. Calculate Vd and Cl based on typical values ​​and make adjustments for factors such as body weight and renal function.

3. Entering the loading dose or maintenance dose, calculated taking into account the values ​​of TC, Vd and Cl.

4. Registration of the patient's reaction and determination of drug concentration

5. Revision of Vd and Cl based on the results of concentration measurements.

6. Repeat steps 3-6 to adjust the maintenance dose required for optimal drug response.

29. Biotransformation of drugs, its biological meaning, main direction and influence on the activity of drugs. The main phases of metabolic transformations of drugs in the body.

Biotransformation of drugs- chemical transformations of drugs in the body.

The biological meaning of biotransformation of drugs: creation of a substrate convenient for subsequent disposal (as an energy or plastic material) or in accelerating the elimination of drugs from the body.

The main direction of metabolic transformations of drugs: non-polar drugs → polar (hydrophilic) metabolites excreted in the urine.

There are two phases of metabolic reactions of drugs:

1) Metabolic transformation (non-synthetic reactions, phase 1)- transformation of substances due to microsomal and extra microsomal oxidation, reduction and hydrolysis

2) conjugation (synthetic reactions, phase 2)- biosynthetic process, accompanied by the addition of a number of chemical groups or molecules of endogenous compounds to a drug or its metabolites by a) the formation of glucuronides b) glycerol esters c) sulfoesters d) acetylation e) methylation

The effect of biotransformation on the pharmacological activity of drugs:

1) most often, biotransformation metabolites do not have pharmacological activity or their activity is reduced in comparison with the initial substance

2) in some cases, metabolites can retain activity and even exceed the activity of the parent substance (codeine is metabolized to more pharmacologically active morphine)

3) sometimes toxic substances are formed during biotransformation (metabolites of isoniazid, lidocaine)

4) sometimes in the course of biotransformation, metabolites with opposite pharmacological properties are formed (metabolites of nonselective agonists of b2-adrenergic receptors have the properties of blockers of these receptors)

5) a number of substances are prodrugs that initially do not give pharmacological effects, but in the course of biotransformation they are converted into biologically active substances (inactive L-dopa, penetrating the BBB, turns into active dopamine in the brain, while there are no systemic effects of dopamine).

30. Clinical significance of drug biotransformation. Influence of gender, age, body weight, environmental factors, smoking, alcohol on the biotransformation of drugs.

Clinical significance of drug biotransformation: since the dose and frequency of administration required to achieve an effective concentration in the blood and tissues can vary in patients due to individual differences in the distribution, metabolic rate and elimination of drugs, it is important to take them into account in clinical practice.

The influence of various factors on the biotransformation of drugs:

A) The functional state of the liver: in case of her diseases, the clearance of drugs usually decreases, and the elimination half-life increases.

B) Influence of environmental factors: smoking promotes the induction of cytochrome P450, as a result of which the metabolism of drugs is accelerated during microsomal oxidation

V) Vegetarians biotransformation of drugs is slowed down

D) in elderly and young patients, hypersensitivity to the pharmacological or toxic effects of drugs is characteristic (in the elderly and in children under 6 months, the activity of microsomal oxidation is reduced)

E) in men, the metabolism of some drugs is faster than in women, since androgens stimulate the synthesis of microsomal liver enzymes (ethanol)

E) High protein content in food and intense physical activity: acceleration of drug metabolism.

F) Alcohol and obesity slow down the metabolism of drugs

31. Metabolic drug interactions. Diseases affecting their biotransformation.

Metabolic interaction of drugs:

1) induction of enzymes of drug metabolism - an absolute increase in their number and activity due to exposure to certain drugs. Induction leads to an acceleration of drug metabolism and (as a rule, but not always) to a decrease in their pharmacological activity (rifampicin, barbiturates - cytochrome P450 inducers)

2) inhibition of enzymes of drug metabolism - inhibition of the activity of metabolic enzymes under the influence of some xenobiotics:

A) competitive metabolic interaction - drugs with high affinity for certain enzymes reduce the metabolism of drugs with a lower affinity for these enzymes (verapamil)

B) binding to a gene that induces the synthesis of certain isoenzymes of cytochrome P450 (cymedin)

C) direct inactivation of cytochrome P450 isoenzymes (flavonoids)

Diseases affecting the metabolism of drugs:

A) kidney disease (impaired renal blood flow, acute and chronic kidney disease, outcomes of long-term renal disease)

B) liver disease (primary and alcoholic cirrhosis, hepatitis, hepatoma)

C) diseases of the gastrointestinal tract and endocrine organs

C) individual intolerance to certain drugs (lack of acetylation enzymes - intolerance to aspirin)

32. Ways and mechanisms of drug excretion from the body. Possibilities of drug elimination control.

Ways and mechanisms of drug excretion: elimination of drugs by the liver and kidneys and some other organs:

A) by the kidneys by filtration, secretion, reabsorption

B) by the liver by biotransformation, excretion with bile

C) through the lungs, saliva, sweat, milk, etc. by secretion, evaporation

Possibilities for managing the processes of drug withdrawal:

1. pH control: in alkaline urine, the excretion of acidic compounds increases, in acidic urine, the excretion of basic compounds

2.use of choleretic drugs (cholenzym, allochol)

3.hemodialysis, peritoneal dialysis, hemosorption, lymphosorption

4.Forced diuresis (IV NaCl or glucose for water load + furosemide or mannitol)

5.gastric lavage, use of enemas

33. The concept of receptors in pharmacology, the molecular nature of receptors, signaling mechanisms of drug action (types of transmembrane signaling and secondary mediators).

Receptors - Molecular components of a cell or organism that interact with drugs and induce a number of biochemical events leading to the development of a pharmacological effect.

The concept of receptors in pharmacology:

1. Receptors determine the quantitative patterns of drug action

2. Receptors are responsible for the selectivity of drug action

3. Receptors mediates the action of pharmacological antagonists

The concept of receptors is the basis for the targeted use of drugs that affect regulatory, biochemical processes and communication.

Molecular nature of receptors:

1.regulatory proteins, mediators of the action of various chemical signals: neurotransmitters, hormones, autocoids

2.enzymes and transmembrane protein carriers (Na +, K + ATPase)

3.structural proteins (tubulin, cytoskeletal proteins, cell surface)

4.nuclear proteins and nucleic acids

Signaling mechanisms of drug action:

1) the penetration of lipid-soluble ligands through the membrane and their effect on intracellular receptors.

2) the signaling molecule binds to the extracellular domain of the transmembrane protein and activates the enzymatic activity of its cytoplasmic domain.

3) the signaling molecule binds to the ion channel and regulates its opening.

4) the signaling molecule binds to a receptor on the cell surface, which is coupled to the effector enzyme via the G-protein. The G-protein activates a secondary messenger.

Types of transmembrane signaling:

A) through 1-TMS receptors with and without tyrosine kinase activity

B) through 7-TMS receptors associated with G-protein

B) through ion channels (ligand-dependent, voltage-dependent, gap contacts)

Secondary intermediaries: cAMP, Ca2 + ions, DAG, IF3.

34. Physicochemical and chemical mechanisms of action of medicinal substances.

A) Physicochemical interaction with a biosubstrate- non-electrolytic action.

The main pharmacological effects: 1) narcotic 2) general depressive 3) paralyzing 4) locally irritating 5) membranolytic action.

Chemical nature of substances: chemically inert hydrocarbons, ethers, alcohols, aldehydes, barbiturates, gas drugs

The mechanism of action is the reversible destruction of membranes.

B) Chemical(molecular-biochemical) mechanism of action of drugs.

The main types of chemical interaction with a biosubstrate:

  1. Weak (non-covalent, reversible interactions) (hydrogen, ionic, monodipole, hydrophobic).
  2. Covalent bonds (alkylation).

The importance of non-covalent drug interactions: the action is nonspecific, does not depend on the chemical structure of the substance.

Significance of drug covalent interactions: the action is specific, critically depends on the chemical structure, is realized through the effect on receptors.

35. Terms and concepts of quantitative pharmacology: effect, efficacy, activity, agonist (full, partial), antagonist. Clinical difference between the concepts of activity and effectiveness of drugs.

Effect (response)- the quantitative yield of the reaction of the interaction of a cell, organ, system or organism with a pharmacological agent.

Efficiency- the measure of the reaction along the axis of the effect - the magnitude of the response of the biological system to the pharmacological effect; This is the ability of drugs to provide the maximum possible effect for it.... That is, in fact, this is the maximum size of the effect that can be achieved with the introduction of a given drug. Numerically characterized by the value of Emax. The higher the Emax, the higher the effectiveness of the drug.

Activity- a measure of sensitivity to drugs along the concentration axis, characterizes the affinity (affinity of the ligand to the receptor), Shows what dose (concentration) of the drug is capable of causing the development of a standard effect equal to 50% of the maximum possible for this drug. Numerically characterized by the value of EC50 or ED50. The higher the drug activity, the lower its dose is required to reproduce the therapeutic effect.

Efficiency: 1 = 2> 3

Activity: 1> 3> 2

In clinical activity, it is more important to know the effectiveness, rather than the activity, since we are more interested in the ability of drugs to cause a certain action in the body.

Agonist- a ligand that binds to the receptor and causes a biological response, the activation of the physiological system. Full agonist- maximum response, Partial- cause less reaction even when all receptors are occupied.

Antagonist- ligands that occupy receptors or change them in such a way that they lose the ability to interact with other ligands, but do not themselves cause a biological reaction (block the action of agonists).

Competitive antagonists- interact with receptors reversibly and thus compete with agonists. Increasing the concentration of the agonist can completely eliminate the effect of the antagonist. The competitive antagonist shifts the dose-response curve for the agonist, increases the EC50, does not affect Emax.

Non-competitive antagonists- irreversibly change the affinity of receptors for the agonist, binding often does not occur with the active site of the receptor, an increase in the concentration of the agonist does not eliminate the effect of the antagonist. A noncompetitive antagonist decreases Emax, does not change EC50, and the dose-effect curve is compressed about the vertical axis.

36. Quantitative patterns of drug action. The law of decreasing the response of biological systems. Clark's model and its consequences. General view of the dependence concentration - effect in normal and lognormal coordinates.

Clark-Ariens model:

1. The interaction between ligand (L) and receptor (R) is reversible.

2. All receptors for a given ligand are equivalent and independent (their saturation does not affect other receptors).

3. The effect is directly proportional to the number of occupied receptors.

4. The ligand exists in two states: free and bound to the receptor.

A) , where Kd is the equilibrium constant, Ke is the internal activity.

B) Since with an increase in the number of ligands at some point in time, all receptors will be occupied, then the maximum possible number of ligand-receptor complexes formed is described by the formula:

= [R] × (1)

The effect is determined by the probability of activation of the receptor upon binding to the ligand, i.e., by its intrinsic activity (Ke), therefore E = Ke ×. In this case, the effect is maximum at Ke = 1 and minimum and Ke = 0. Naturally, the maximum effect is described by the ratio Emax = Ke ×, where is the total number of receptors for a given ligand

The effect also depends on the concentration of the ligand on the [C] receptors, therefore

E = Emax (2)

It follows from the above relations that EC50 = Kd

Emax is the maximum effect, Bmax is the maximum number of bound receptors, EC50 is the drug concentration at which an effect equal to half of the maximum occurs, Kd is the constant of dissociation of the substance from the receptor, at which 50% of the receptors are bound.

The law of decreasing response the parabolic dependence "concentration - efficiency" corresponds. The response to low doses of drugs usually increases in direct proportion to the dose... However, as the dose is increased, the increase in response decreases and eventually a dose can be reached at which there is no further increase in response (due to the occupation of all receptors for a given ligand).

37. Changing the effect of drugs. Gradual and quantum evaluation of the effect, essence and clinical applications. Measures for quantifying the activity and effectiveness of drugs in experimental and clinical practice.

All pharmacological effects can be roughly divided into two categories:

A) Gradual (continuous, integral) effects- such effects of drugs that can be measured quantitatively (the effect of antihypertensive drugs - by the level of blood pressure). A gradual "dose-effect curve" (see p. 36) is described, on the basis of which it is possible to estimate: 1) individual sensitivity to drugs 2) drug activity 3) maximum drug efficacy

B) Quantum Effects- such effects of drugs, which are a discrete value, a qualitative sign, i.e., they are described by only a few variants of conditions (headache after taking an analgesic, either present or not). A quantum dose-effect curve is described, where the dependence of the manifestation of the effect in the population on the value of the taken drug dose is noted. The dose-effect plot is dome-shaped and is identical to the Gaussian normal distribution curve. Based on the quantum curve, one can: 1) assess the population sensitivity of drugs; 2) note the presence of an effect at a given dose; 3) select an average therapeutic dose.

Differences between gradual and quantum dose-effect characteristics:

A quantitative assessment of the activity and effectiveness of drugs is carried out on the basis of the construction of dose-effect curves and their subsequent assessment (see paragraph 35)

38. Types of drugs action. Changes in the action of drugs when they are re-administered.

Types of drug action:

1. Local action- the effect of a substance that occurs at the site of its application (anesthetic - on the mucous membrane)

2. Resorptive (systemic) action- the effect of a substance that develops after its absorption, entry into the general bloodstream, and then into the tissues. Depends on the routes of drug administration and their ability to penetrate biological barriers.

With both local and resorptive action, drugs can have either Direct or Reflex influence:

A) direct influence - direct contact with the target organ (adrenaline on the heart).

B) reflex - a change in the function of organs or nerve centers by influencing extero - and interoreceptors (mustard plasters reflexively improve their trophism in respiratory pathology)

Changes in the action of drugs when they are reintroduced:

1. Cumulation- an increase in the effect due to the accumulation of drugs in the body:

a) material cumulation - the accumulation of an active substance in the body (cardiac glycosides)

b) functional cumulation - increasing changes in the function of body systems (changes in the function of the central nervous system in chronic alcoholism).

2. Tolerance (addiction) - Decrease in the body's response to repeated drug injections; in order to restore the reaction to drugs, it has to be administered in larger and larger doses (diazepam):

A) true tolerance - observed both with enteral and parenteral administration of drugs, does not depend on the degree of its absorption into the bloodstream. It is based on pharmacodynamic mechanisms of addiction:

1) desensitization - a decrease in the sensitivity of the receptor to the drug (b-adrenergic agonists, with prolonged use, lead to phosphorylation of b-adrenergic receptors, which are unable to respond to b-adrenergic agonists)

2) Down-regulation - a decrease in the number of drug receptors (with repeated administration of narcotic analgesics, the number of opioid receptors decreases and more and more doses of the drug are required to induce the desired response). If a drug blocks receptors, then the mechanism of tolerance to it may be associated with up-regulation - an increase in the number of drug receptors (b-blockers)

3) the inclusion of compensatory mechanisms of regulation (with repeated injections of antihypertensive drugs, collapse occurs much less often than with the first administration due to the adaptation of baroreceptors)

B) relative tolerance (pseudo-tolerance) - develops only with the introduction of drugs inside and is associated with a decrease in the rate and completeness of drug absorption

3. Tachyphylaxis- a condition in which frequent administration of drugs causes the development of tolerance after a few hours, but with rather rare administrations of drugs, its effect is fully preserved. The development of tolerance is usually associated with the depletion of the effector systems.

4. Drug addiction- an irresistible desire to take a substance previously administered. Allocate mental (cocaine) and physical (morphine) drug addiction.

5. Hypersensitivity- an allergic or other immunological reaction to drugs upon repeated administration.

39. The dependence of the action of drugs on age, sex and individual characteristics of the organism. The meaning of circadian rhythms.

A) From age: in children and the elderly, the sensitivity to drugs is increased (because children have a deficiency of many enzymes, renal function, increased BBB permeability, absorption of drugs is slowed down in old age, metabolism is less efficient, the rate of excretion of drugs by the kidneys is reduced):

1. Newborns have reduced sensitivity to cardiac glycosides, since they have more Na + / K + -ATPases (targets of glycoside action) per unit area of ​​the cardiomyocyte.

2. Children have lower sensitivity to succinylcholine and atracuria, but increased sensitivity to all other muscle relaxants.

3. Psychotropic drugs can cause abnormal reactions in children: psychostimulants - can increase concentration and reduce motor hyperactivity, tranquilizers - on the contrary, can cause so-called. atypical agitation.

1. The sensitivity to cardiac glycosides increases sharply due to a decrease in the number of Na + / K + -ATPases.

2. Decreases sensitivity to b-blockers.

3. The sensitivity to calcium channel blockers increases, since the baroreflex is weakened.

4. There is an atypical reaction to psychotropic drugs, similar to the reaction of children.

B) From the floor:

1) antihypertensive drugs - clonidine, b-blockers, diuretics can cause sexual dysfunctions in men, but do not affect the functioning of the reproductive system of women.

2) anabolic steroids are more effective in women than in men.

V) From the individual characteristics of the organism: deficiency or excess of certain enzymes of drug metabolism leads to an increase or decrease in their action (deficiency of blood pseudocholinesterase - abnormally prolonged muscle relaxation when using succinylcholine)

G) From circadian rhythms: change in the effect of drugs on the body, quantitatively and qualitatively, depending on the time of day (maximum effect with maximum activity).

40. Variability and variability of drug action. Hypo - and hyperreactivity, tolerance and tachyphylaxis, hypersensitivity and idiosyncrasy. Reasons for the variability of drug action and rational therapy strategy.

Variability reflects the differences between individuals in response to a given drug.

The reasons for the variability of the drug action:

1) a change in the concentration of a substance in the receptor zone - due to differences in the rate of absorption, its distribution, metabolism, elimination

2) variations in the concentration of the endogenous ligand of the receptor - propranolol (β-blocker) slows down the heart rate in people with increased levels of catecholamines in the blood, but does not affect the background heart rate in athletes.

3) changes in the density or function of receptors.

4) changes in the reaction components located distal to the receptor.

Rational therapy strategy: the appointment and dosage of drugs, taking into account the above reasons for the variability of drug action.

Hyporeactivity- a decrease in the effect of a given dose of drugs in comparison with the effect that is observed in most patients. Hyperreactivity- an increase in the effect of a given dose of drugs in comparison with the effect that is observed in most patients.

Tolerance, tachyphylaxis, hypersensitivity - see item 38

Idiosyncrasy- a perverted reaction of the body to a given drug, associated with the genetic characteristics of drug metabolism or with individual immunological reactivity, including with allergic reactions.

41. Assessment of drug safety. Therapeutic index and standard safety margins.

Safety assessment is carried out at two levels:

A) preclinical (obtaining information on the toxicity of drugs, effects on reproductive functions, embryotoxicity and teratogenicity, long-term effects)

B) clinical (further assessment of the effectiveness and safety of drugs)

If after the plateau of the effect is reached, the dose of the drug continues to grow, then after a certain period of time its toxic effect will begin to manifest itself. The dependence of the toxic effect on the dose (concentration) of the drug is of the same nature as its beneficial effect and can be described by gradual or quantum curves. These curves can also be used to determine the value TD50 or TC50- toxic dose (concentration) of drugs, which causes a toxic effect equal to 50% of the maximum (for a quantum curve - toxic effect in 50% of individuals in the population). Sometimes, instead of TD50, they use the indicator LD50 - lethal dose, which causes the death of 50% of objects in the population.

The safety assessment of a drug is characterized on the basis of gradule or quantum dose-effect curves and the following indicators:

A) Therapeutic index Is the ratio between the toxic and effective doses of the drug, which cause the appearance of a half-maximal effect: TI = TD50 / ED50. The higher the value of the therapeutic index, the safer the medicine is.

B) Therapeutic latitude (therapeutic window) Is the dose range between the minimum therapeutic and minimum toxic doses of drugs. It is a more correct indicator of drug safety, since it allows one to take into account the degree of increase in undesirable effects on the dose-effect curve.

V) Reliable safety factor- this is the ratio of the minimum toxic dose to the maximum effective dose (PNF = TD1 / ED99), shows how many times the therapeutic dose of a drug can be exceeded without the risk of intoxication (undesirable effects).

G) Therapy corridor Is the range of effective concentrations of a drug in the blood that must be created and maintained in the body in order to achieve the desired therapeutic effect.

42.46. Interaction of drugs. Incompatibility of drugs (since the questions are interrelated, choose according to the circumstances)

Drug interaction- this is a change in the severity and nature of the effects with the simultaneous or preliminary use of several drugs.

Reasons for unwanted interactions:

1) polypharmacy - 6 or more drugs give 7 times more side effects than if drugs are less than 6.

2) doctors' mistakes

3) violation of the dosage regimen

Rationale for combination therapy:

1. Monotherapy is not effective enough.

2. Absence of etiotropic therapy in most diseases Þ the need for drug action on different links of pathogenesis

3. Polymorbidity - the older a person is, the more diseases he has that occur simultaneously

4. The need to correct the unwanted effects of drugs

5. Reducing the number of receptions and administration of drugs (convenience for the patient, saving the labor of health workers)

Types of interaction:

I. Pharmaceutical interactions - The type of interaction associated with a physicochemical reaction between drugs during the manufacture of a medicinal product, even before the introduction of these funds into the human body

A) typical mistakes leading to pharmaceutical incompatibility: writing out complex prescriptions, improper storage, the possibility of adsorption of drugs on the surface of plastic (organic nitrates) is not taken into account

B) problems with infusion therapy: mixing of soluble salts, derivatives of insoluble weak acids or bases leads to their precipitation; in liquid dosage forms, cardiac glycosides and alkaloids are hydrolyzed, AB is destroyed; pH of the medium (alkaloids precipitate in an alkaline medium)

C) recommendations: 1) It is better to prepare all mixtures ex tempore 2) The most reliable solution is with one drug 3) All solutions must be checked for suspensions before use 4) Interaction can occur without visible changes in solutions 5) Drugs cannot be added to blood and AK solutions 6) In the absence of special instructions, the preparations should be dissolved in 5% glucose solution (pH 3.5-6.5), isotonic NaCl solution (pH 4.5-7.0).

HCl-stabilized glucose solution is incompatible with epinephrine, benzylpenicillin, apomorphine, kanamycin, vitamin C, oleandomycin, cardiac glycosides. Cardiac glycosides are incompatible with atropine, papaverine, platifillin. AB are incompatible with heparin, hydrocortisone. Vitamins of group B are incompatible with each other, with vitamins PP, C. Vitamins PP and C are also incompatible with each other.

Cannot be mixed with any other drugs: phenothiazide, chlorpromazine, barbiturates, vitamin C preparations, amphotericin B, furosemide, sulfadiazine, aminophylline, adrenomimetics.

II... Pharmacological- drug interaction, which manifests itself only in the human body after their combined use

A) pharmacokinetic

1) during the suction phase.

When introducingPer Osinteraction is determined by:

1.acidity of the environment

2.direct interaction in the digestive tract

Tetracyclines interact with calcium, aluminum, iron, magnesium to form chelate complexes. Cholestyramine interferes with the absorption of acid derivatives, calcium preparations, varvarine, digoxin, digitoxin, fat-soluble vitamins, trimethoprim, clindamycin, cephalexin, tetracycline. Iron preparations are better absorbed with vitamin C. Iron preparations with carbonates, tetracyclines are poorly absorbed.

3.Gastrointestinal motility

Slow down peristalsis: some antidepressants, antihistamine drugs, phenothiazine antipsychotic drugs, narcotic drugs, increase the absorption of digoxin, corticosteroids, anticoagulants, reduce the absorption of levodopa. Strengthen peristalsis and increase evacuation from the gastrointestinal tract: metoclopramide, laxatives. Reduces the absorption of drugs: phenobarbital - griseofulvin, aspirin - indomethacin and diclofenac, PASK - rifampicin.

Methods for controlling absorption during parenteral administration: local anesthetics + epinephrine + phenylephrine - absorption of local anesthetics decreases

4.intestinal flora

5.changing the suction mechanism

2) when distributing and depositing:

1.direct interaction in blood plasma: gentamicin + ampicillin or carbenicillin - reduce the activity of gentamicin

2. competitive displacement from the connection with albumin in the blood plasma: indomethacin, digitoxin, warfarin are associated with blood proteins by 90-98%, therefore, a twofold increase in the free fraction of drugs is a sharp increase in toxic effects; NSAIDs are replacing: warfarin, phenytoin, methotrexate.

Determinants for the clinical significance of this interaction:

ü Vd value (large - no problem, small - possible)

ü the effect of one drug substance on the activity of transport mechanisms through the mechanisms of other drugs: the drug transport increases in a dose-dependent manner - insulin, ACTH, angiotensin, kinins, etc .; insulin increases the concentration of isoniazid only in the lungs, and the concentration of cottonromazine - only in the SMC.

3.Displacement from tissue protein binding: quinidine displaces digoxin + reduces renal excretion, therefore increasing the risk of digoxin toxicity

3) in the process of metabolism

Drugs can increase or decrease the activity of cytochrome P450 and its enzymes (ethanol increases the activity of certain cytochrome isoenzymes)

Frequently interacting enzyme inhibitors:

1. AB: ciprofloxacin, erythromycin, isoniazid, metronidazole

2. Cardiovascular drugs: amiodarone, diltiazem, quinidine, verapamil

3. Antidepressants: fluoxetine, sertralene

4. Antisecretory drugs: cimetidine, omeprazole

5. Antirheumatic drugs: allopurinol

6. Fungicides: fluconazole, intracanazole, ketoconazole, miconazole

7. Antivirals: indinavir, retonavir, saquinavir

8. Others: disulfiram, sodium valproate

Drugs that give toxic effects in MAO inhibition: adrenomimetics, sympathomimetics, antiparkinsonian, narcotic analgesics, phenothiazines, sedatives, antihypertensive diuretics, hypoglycemic drugs

4) In the process of hatching- more than 90% of drugs are excreted in the urine.

Effect on urine pH and on the degree of drug ionization, on their lipophilicity and their reabsorption

1.interaction during passive diffusion: part of the drug is excreted unchanged, part of the drug is ionized at urine pH 4.6-8.2. Alkalinization of urine is clinically important: poisoning with acetylsalicylic acid or phenobarbital, when taking sulfonamides (reducing the risk of crystalluria), taking quinidine. Increased urine acidity: increased excretion of amphetamine (of practical importance for the detection of this drug in athletes)

2.interaction during the period of active transport: probenezid + penicillin increases the duration of the movement of penicillin, probenecid + salicylates - elimination of the uricosuric action of probenecid, penicillin + CA - a decrease in the excretion of penicillin

Influence of urine composition on drug excretion:

An increase in sugar in urine - an increase in excretion of: vitamin C, chloramphenicol, morphine, isoniazid, glutathione and their metabolites.

B) pharmacodynamic Is the interaction of drugs associated with a change in the pharmacodynamics of one of them under the influence of the other (under the influence of thyroid hormones, the synthesis of b-adrenergic receptors in the myocardium increases and the effect of adrenaline on the myocardium increases).

Examples of clinically significant undesirable synergistic interactions:

NSAIDs + varvarine - increased risk of bleeding

Alcohol + benzodiazepines - potentiation of the sedative effect

ACE inhibitors + K + -saving diuretics - increased risk of hyperkalemia

Verapamil + b-blockers - bradycardia and asystole

Alcohol is a strong inducer of microsomal enzymes, leads to the development of tolerance to drugs (especially to anesthetic and hypnotics), increases the risk of drug dependence.

43. Drug interaction. Antagonism, synergy, their types. The nature of the change in the effect of drugs (activity, effectiveness) depending on the type of antagonism.

When a drug interacts, the following conditions may develop: a) an increase in the effects of a drug combination b) a weakening of the effects of a drug combination c) drug incompatibility

Strengthening the effects of a combination of drugs is implemented in three ways:

1) Summation of effects or additive interaction- the type of drug interaction in which the effect of the combination is equal to the simple sum of the effects of each of the drugs separately. Ie. 1+1=2 ... It is characteristic of drugs from one pharmacological group that have a common target of action (the acid-neutralizing activity of a combination of aluminum and magnesium hydroxide is equal to the sum of their acid-neutralizing abilities separately)

2) synergy - a type of interaction in which the effect of a combination exceeds the sum of the effects of each of the substances taken separately. Ie. 1+1=3 ... Synergy can relate to both the desired (therapeutic) and undesirable effects of drugs. The combined administration of the thiazide diuretic dichlothiazide and the ACE inhibitor enalapril leads to an increase in the hypotensive effect of each of the agents, which is used in the treatment of hypertension. However, the simultaneous administration of aminoglycoside antibiotics (gentamicin) and the loop diuretic furosemide causes a sharp increase in the risk of ototoxic action and the development of deafness.

3) potentiation - a type of drug interaction in which one of the drugs, which in itself does not have this effect, can lead to a sharp increase in the effect of another drug. Ie. 1+0=3 (clavulanic acid does not have an antimicrobial effect, but it can enhance the effect of the b-lactam antibiotic amoxicillin due to the fact that it blocks b-lactamase; adrenaline does not have a local anesthetic effect, but when added to the ultracaine solution, it sharply lengthens its anesthetic effect by slowing down absorption anesthetic from the injection site).

Attenuating Effects Drugs when used together are called antagonism:

1) Chemical antagonism or antidote- chemical interaction of substances with each other with the formation of inactive products (a chemical antagonist of iron ions deferoxamine, which binds them into inactive complexes; protamine sulfate, a molecule of which has an excess positive charge - a chemical antagonist of heparin, a molecule of which has an excess negative charge). Chemical antagonism underlies the action of antidotes (antidotes).

2) Pharmacological (direct) antagonism- antagonism caused by the multidirectional action of 2 medicinal substances on the same receptors in the tissues. Pharmacological antagonism can be competitive (reversible) and non-competitive (irreversible):

A) competitive antagonism: a competitive antagonist reversibly binds to the active center of the receptor, i.e. shields it from the action of the agonist. Since the degree of binding of a substance to a receptor is proportional to the concentration of this substance, the effect of a competitive antagonist can be overcome by increasing the concentration of the agonist. It will displace the antagonist from the active site of the receptor and induce a full tissue response. That. a competitive antagonist does not alter the maximum effect of the agonist, but a higher concentration is required for the agonist to interact with the receptor. Competitive antagonist Shifts the dose-response curve for the agonist to the right relative to the initial values ​​and increases the EC50 for the agonist without affecting the E value Max.

Competitive antagonism is often used in medical practice. Since the effect of a competitive antagonist can be overcome if its concentration falls below the level of the agonist, during treatment with competitive antagonists it is necessary to constantly maintain its level sufficiently high. In other words, the clinical effect of a competitive antagonist will depend on its elimination half-life and the concentration of the full agonist.

B) non-competitive antagonism: a non-competitive antagonist binds almost irreversibly to the active center of the receptor or interacts in general with its allosteric center. Therefore, no matter how the concentration of the agonist increases, it is not able to displace the antagonist from its connection with the receptor. Since some of the receptors that are associated with a non-competitive antagonist are no longer able to be activated , the value of EMax decreases, the affinity of the receptor for the agonist does not change, so the EC50 value remains the same. On the dose-response curve, the action of a non-competitive antagonist manifests itself as compression of the curve relative to the vertical axis without shifting it to the right.

Scheme 9. Types of antagonism.

A - the competitive antagonist shifts the dose-effect curve to the right, ie, it reduces the tissue sensitivity to the agonist without changing its effect. B - a noncompetitive antagonist reduces the magnitude of the tissue response (effect), but does not affect its sensitivity to the agonist. C - a variant of using a partial agonist against the background of a full agonist. As the concentration increases, the partial agonist displaces the complete one from the receptors and, as a result, the tissue response decreases from the maximum response to the full agonist, to the maximum response to the partial agonist.

Non-competitive antagonists are used less frequently in medical practice. On the one hand, they have an undoubted advantage, since their effect cannot be overcome after binding to the receptor, and therefore does not depend on the half-elimination period of the antagonist or on the level of the agonist in the body. The effect of a non-competitive antagonist will be determined only by the rate of synthesis of new receptors. But on the other hand, if an overdose of this medication occurs, it will be extremely difficult to eliminate its effect.

Competitive antagonist

Non-competitive antagonist

Similar in structure to an agonist

Structurally different from an agonist

Binds to the active center of the receptor

Binds to the allosteric site of the receptor

Shifts the dose-response curve to the right

Shifts the dose-response curve vertically

The antagonist reduces tissue sensitivity to the agonist (EC50), but does not affect the maximum effect (Emax) that can be achieved at a higher concentration.

The antagonist does not alter the tissue sensitivity to the agonist (EC50), but decreases the internal activity of the agonist and the maximum tissue response to it (Emax).

Antagonist action can be reversed with a high dose of the agonist

The antagonist effect cannot be reversed with a high dose of the agonist.

The effect of the antagonist depends on the dose ratio of the agonist and the antagonist

The effect of the antagonist depends only on its dose.

Losartan is a competitive antagonist against the AT1 receptors of angiotensin; it disrupts the interaction of angiotensin II with receptors and helps to lower blood pressure. The effects of losartan can be overcome by administering a high dose of angiotensin II. Valsartan is a non-competitive antagonist for the same AT1 receptors. Its effect cannot be overcome even with the administration of high doses of angiotensin II.

Interesting is the interaction that takes place between the full and partial receptor agonists. If the concentration of the full agonist exceeds the level of the partial one, then the maximum response is observed in the tissue. If the level of the partial agonist begins to rise, it displaces the full agonist from binding to the receptor, and the tissue response begins to decrease from the maximum for the full agonist to the maximum for the partial agonist (i.e., the level at which it occupies all receptors).

3) Physiological (indirect) antagonism- antagonism associated with the influence of 2 drugs on various receptors (targets) in tissues, which leads to a mutual weakening of their effect. For example, physiological antagonism is observed between insulin and adrenaline. Insulin activates insulin receptors, as a result of which the transport of glucose into the cell increases and the level of glycemia decreases. Epinephrine activates the b2-adrenergic receptors of the liver, skeletal muscles and stimulates the breakdown of glycogen, which ultimately leads to an increase in glucose levels. This type of antagonism is often used in the emergency care of patients with an insulin overdose that has led to hypoglycemic coma.

44. Side and toxic effects of drugs. Teratogenic, embryotoxic, mutagenic effects of drugs.

Side effects- those effects that occur when substances are used in therapeutic doses and constitute the spectrum of their pharmacological action (the analgesic morphine in therapeutic doses causes euphoria) can be primary and secondary:

A) primary side effects - as a direct consequence of the effect of this drug on a certain substrate (hyposalivation when using atropine to eliminate bradyarrhythmia)

B) secondary side effects - indirectly occurring adverse effects (AB, suppressing normal microflora, can lead to superinfection)

Toxic effects- undesirable effects manifested in this drug when it leaves the therapeutic range (drug overdose)

The selectivity of the drug action depends on its dose. The higher the dose of the drug, the less selective it becomes.

Teratogenic action- the ability of drugs, when administered to a pregnant woman, to cause anatomical anomalies of fetal development (thalidomide: phocomelia, antiblastoma drugs: multiple defects)

Embryotoxic action- an adverse effect that is not associated with a violation of organogenesis in the first three months of pregnancy. At a later date, it appears Fetotoxic action.

Mutagenic effect of drugs- damage to the germ cell and its genetic apparatus of drugs, which is manifested by a change in the genotype of the offspring (adrenaline, cytostatics).

Carcinogenic effect of drugs- the ability of some drugs to induce carcinogenesis.

45. Medical and social aspects of combating drug dependence, drug addiction and alcoholism. The concept of substance abuse.

« It is unlikely that humanity as a whole will ever do without an artificial paradise. Most men and women lead such a painful life, which at best is so monotonous, wretched and limited that the desire to "leave" it, to disconnect at least for a few moments, is and has always been one of the main Wished Ny soul"(Huxley, work" The Doors of Perception ")

1) Drug addiction- a state of mind and / or a physical state, which is a consequence of the effect on the body of drugs and is characterized by specific behavioral reactions, it is difficult to overcome the desire to re-take drugs in order to achieve a special mental effect or to avoid discomfort in the absence of drugs in the body. Drug dependence is characterized by:

A) Psychological addiction- the development of emotional distress when you stop taking drugs. A person feels empty, plunges into depression, experiences a feeling of fear, anxiety, his behavior becomes aggressive. All these psychopathological symptoms arise against the background of thoughts about the need to inject yourself with a drug that has caused addiction. The desire to take drugs can range from a simple desire to a passionate thirst for taking drugs, which absorbs all other needs and turns into the meaning of a person's life. It is believed that psychological dependence develops when a person becomes aware that he can achieve optimal well-being solely through the introduction of drugs. The basis of psychological dependence is a person's belief in the action of the drug (cases of the development of psychological dependence on placebo are described in the literature).

B) Physical addiction- violation of the normal physiological state of the body, which requires the constant presence of drugs in it to maintain a state of physiological balance. Stopping the medication causes the development of a specific symptom complex - withdrawal syndrome - a complex of mental and neurovegetative disorders in the form of a dysfunction in the direction opposite to that which is characteristic of the action (morphine eliminates pain, depresses the respiratory center, narrows the pupils, causes constipation; with withdrawal symptoms, the patient develops excruciating pain, frequent noisy breathing, pupils are dilated and persistent diarrhea develops)

V) Tolerance... Tolerance to drugs that cause drug dependence is often cross-cutting, that is, it arises not only to a given chemical compound, but also to all structurally similar compounds. For example, in patients with drug dependence to morphine, tolerance arises not only to it, but also to other opioid analgesics.

For the development of drug dependence, the presence of all 3 criteria is not a necessary condition; Table 3 shows the main types of drug dependence and its constituent components.

Opioids, barbiturates, alcohol cause strong physical and psychological dependence and tolerance. Anxiolytics (diazepam, alprazolam) predominantly cause psychological dependence.

2) Addiction (drug addiction)- This is an extremely severe form of drug dependence, compulsive use of drugs, characterized by an ever-increasing, irresistible urge to administer this drug, increasing its dose. Desire compulsiveness means that the need to administer the drug dominates all other (even vital) needs in the patient. From the standpoint of this definition, craving for morphine is drug addiction, while craving for nicotine is drug dependence.

3) Addicted to medicine- characterizes a less intense craving for medication, when refusal from medication causes only a feeling of mild discomfort, without the development of physical dependence or a detailed picture of psychological dependence. That. addiction encompasses that part of drug addiction that does not fit the definition of addiction. For example, the aforementioned drug addiction to nicotine is a form of addiction.

4) Drug abuse- unauthorized use of drugs in such doses and in such ways that differ from the accepted medical or social standards in a given culture and at a given time. That. drug abuse covers only the social aspects of drug use. An example of abuse is the use of anabolic steroids in sports or to improve physique by young men.

5) Alcoholism- chronic abuse of alcohol (ethyl alcohol), leading nowadays to damage to a number of organs (liver, gastrointestinal tract, central nervous system, cardiovascular system, immune system) and accompanied by psycho-physical dependence.

6) Substance abuse- chronic abuse of various drugs (including drugs, alcohol, hallucinogens), manifested by a variety of mental and somatic disorders, behavioral disorders, social degradation.

Drug addiction treatment difficult and thankless task. Until now, no effective method has been created that would ensure the success of treatment in more than 30-40% of patients. Achievement of any noticeable results is possible only with the full cooperation of the efforts of the patient, the doctor and the social environment in which the sick person is (the principle of voluntariness and individuality). The modern techniques are based on the following principles:

ü psychotherapeutic and occupational therapy methods;

ü group treatment and rehabilitation (society of alcoholics anonymous, drug addicts)

ü gradual or abrupt withdrawal of the drug against the background of detoxification therapy

ü carrying out substitution therapy (replacing the drug with slow and long-acting analogues with their subsequent cancellation; for example, the so-called methadone substitution therapy program for heroin addicts)

ü treatment with specific antagonists (naloxone and naltrexone) or sensitizing agents (teturam)

ü neurosurgical methods of cryodestruction of the cingulate gyrus and hippocampus

47. Types of pharmacotherapy. Deontological problems of pharmacotherapy.

Pharmacotherapy (FT) - a set of treatment methods based on the use of drugs. The main types of FT:

1.etiotropic PT - correction and elimination of the cause of the disease (AB in infectious diseases)

2.pathogenetic FT - impact on the mechanism of disease development (ACE inhibitors in hypertension)

3.symptomatic FT - elimination of the symptoms of the disease if it is impossible to influence its cause or pathogenesis (NSAIDs for influenza)

4.Substitution FT - the use of drugs in case of insufficiency of natural biologically active substances (insulin in diabetes)

5.prophylactic FT (vaccines, serums, acetylsalicylic acid for ischemic heart disease)

Society's attitude to drugs at the present stage: 1) desire to get benefits without risk 2) hope for a miracle, visions 3) misunderstanding of the risk of drug use 4) indignation and "righteous indignation", hasty drug assessments 5) desire to get new drugs

Doctor's attitude to drugs: therapeutic optimism (reliance on drugs as a powerful component of therapy), therapeutic nihilism (denial of new drugs, adherence to certain drugs, distrust of new drugs)

Compliance (adherence) of the patient to treatment 1) understanding the doctor's instructions and treatment goals 2) striving to follow the doctor's prescriptions exactly.

Currently, there are about 100,000 drugs in the world, more than 4,000 are registered in the Republic of Belarus, of which about 300 are vital drugs. The study of pharmacology helps not to drown in the sea of ​​drugs.

48. Basic principles of treatment and prevention of drug poisoning. Antidote therapy.

Classification of toxic substances (OM):

1. By belonging to certain classes of chemical compounds: barbiturates, benzodiazepines, cyanides.

2. By origin: non-biological nature (acids, alkalis, salts of heavy metals), toxic waste products of some MB (botulinum toxin), plant origin (alkaloids, glycosides), animal origin (snake and bee venom)

3. According to the degree of toxicity: a) extremely toxic (DL50< 1 мг/кг) б) высоко токсические (1-50) в) сильно токсические (50-500) г) умеренно токсические (500-5000) д) мало токсические (5000-15000) е) практически нетоксические (> 15.000)

4. By toxicological effect: a) nerve-paralytic (bronchospasm, dyspnea) b) skin-resorptive c) general toxic (hypoxic convulsions, coma, paralysis) d) suffocating e) lacrimal and irritating e) psychotropic (impaired mental activity, consciousness)

5. Depending on the area of ​​preferential use: industrial poisons, pesticides, household poisons, chemical warfare agents, medicinal substances.

6. Depending on the toxicity of drugs: List A - drugs, the purpose, use, dosing and storage of which, due to their high toxicity, should be done with great care. The same list includes drugs that cause drug addiction; list B - drugs, the appointment, use, dosing and storage of which should be carried out with caution in connection with possible complications when using them without medical supervision.

Selectively toxic effect of drugs.

A) cardiotoxic: cardiac glycosides, potassium preparations, antidepressants

B) neurotoxic: psychopharmacological agents, oxyquinolines, aminoglycosides

B) hepatotoxic: tetracyclines, chloramphenicol, erythromycin, paracetamol

D) nephrotoxic: vancomycin, aminoglycosides, sulfonamides

E) gastroenterotoxic: steroid anti-inflammatory drugs, NSAIDs, reserpine

E) hematotoxic: cytostatics, chloramphenicol, sulfonamides, nitrates, nitrites

G) pneumotoxic

Toxicokinetics - studies the absorption, distribution, metabolism and excretion of drugs taken in toxic doses.

The entry of toxic substances into the body is possible a) enterally b) parenterally. The speed and completeness of absorption reflects the rate of development of the toxic effect and its severity.

Distribution in the body: Vd = D / Cmax - the actual volume in which the poisonous substance is distributed in the body. Vd> 5-10 l / kg - OM is difficult to tolerate for its removal (antidepressants, phenothiazines). Vd< 1 л/кг – ОВ легче удалить из организма (теофиллин, салицилаты, фенобарбитал).

Overdose- changes in pharmacokinetic processes: solubility, connection with proteins, metabolism ® significant increase in the free fraction of drugs ® toxic effect.

The kinetics of the first order with an increase in the concentration of the drug transforms into the kinetics of the zero order.

The toxigenic stage is detoxification therapy, the somatogenic stage is symptomatic therapy.

Toxicodynamics . The main mechanisms of toxic action:

A) mediator: direct (by the type of competitive blockade - FOS, psychomimetics) and indirect (activators or inhibitors of enzymes)

B) interaction with biomolecules and intracellular structures (hemolytic substances)

C) metabolism by the type of lethal synthesis (ethyl alcohol, thiophos)

D) enzymatic (snake venoms, etc.)

Types of action: local, reflex, resorptive.

Poisoning classification:

1. Etiopathogenetic:

a) accidental (self-medication, mistaken reception)

b) deliberate (with the aim of suicide, murder, development of a helpless state in the victim)

2. Clinical:

a) depending on the rate of development of poisoning: acute (intake of a single dose or with a short time interval of a toxic dose of a substance), subacute (delayed development of the clinical picture after a single dose), chronic

b) depending on the manifestation of the main syndrome: damage to the CVS, damage to the DS, etc.

c) depending on the severity of the patient's condition: mild, moderate, severe, extremely severe

3. Nosological: takes into account the name of the drug, the name of the group of substances

General mechanism of death in case of poisoning:

A) defeat of CVS:

1) lowering blood pressure, hypovolemia of peripheral vessels, collapse, brady - or tachycardia (tricyclic antidepressants, beta-blockers, calcium channel blockers)

2) arrhythmias (ventricular tachycardia, fibrillation - tricyclic antidepressants, theophylline, amphetamine)

B) damage to the central nervous system: stupor, coma ® respiratory depression (drugs, barbiturates, alcohol, hypno-sedative drugs)

C) convulsions, muscle hyperreactivity and rigidity ® hyperthermia, myoglobinuria, renal failure, hyperkalemia

Toxicological triad:

1) duration of use, dose and substance ® history.

2) assessment of the state of consciousness by symptoms: respiration, blood pressure, body temperature

3) laboratory data

Basic principles of treatment:

I. First aid: artificial respiration, heart massage, anti-shock therapy, control of water-electrolyte balance

II... Delayed absorption and removal of non-absorbed OM from the body:

Purpose: to end contact with OV

1. Parenteral route:

a) through the lungs:

1) stop inhalation

2) irritating substances (ammonia, formaldehyde) ® to consolidate active movements, warm up, give oxygen and defoamers (for ammonia, the defoamer is vinegar, and for formaldehyde, a diluted solution of ammonia)

b) through the skin: wash off with copious amounts of warm water with soap or detergent, specific antidotes, neutralization and termination of the exposure to OM on the skin (FOS: wash with water, remove with 10-15% ammonia or 5-6% sodium bicarbonate solution with water; phenolcresol: vegetable oil or ethylene glycol, but not vaseline oil, KMNO4: 0.5-1% ascorbic acid solution or equal volumes of 3% hydrogen peroxide and 3% acetic acid solution, CCl4, turpentine, gasoline: warm soapy water )

c) when injected into a limb: a tourniquet above the injection site

d) in case of eye contact: rinse with warm saline or milk for 10-20 minutes, drip a local anesthetic; in case of contact with acids and alkalis, they cannot be neutralized. Consultation with an ophthalmologist is required.

2. Enteral route: to free the stomach from OM, to accelerate the passage

a) removal of OM:

1) preliminary intake of water. Do not take milk (with the exception of caustic poisonous substances) and ethanol (with the exception of methanol).

2) vomiting - indicated mainly in case of poisoning with large tablets or capsules that cannot pass through the probe. Can be provoked by reflex or emetic (NaCl: 1 tablespoon per 1 glass of water; Ipecac syrup: adults 2 tablespoons, children 2 teaspoons; mustard: 1-2 teaspoons per glass of water; apomorphine: 5-10 mg / kg subcutaneously , except for children under 5 years old). Do not induce vomiting after ingestion: organic solvents - danger of inhalation, detergents - foaming, convulsive substances - danger of aspiration, caustic substances - damage to the esophagus)

3) probe gastric lavage - is an emergency and mandatory measure. The stomach is washed if no more than 4-6 hours have passed since the poisoning, sometimes up to 10 hours; in case of poisoning with acetylsalicylic acid - after 24 hours. The patient is pre-intubated with a tube with an inflatable cuff: in a coma in the absence of a cough and laryngeal reflex. The stomach is washed with water or saline solution 30 ° C, the procedure takes 4 hours or more. At the end of the wash, activated carbon and sodium sulfate.

b) decrease in absorption from the gastrointestinal tract: activated charcoal inside after gastric emptying + sodium or magnesium sulfate. Features of measures to reduce absorption:

1) organic solvents: do not induce vomiting, gastric lavage after intubation, activated carbon + liquid paraffin

2) detergents: do not induce vomiting and wash out the stomach, it is necessary to give a lot of water + antifoaming agents (simethicone)

3) acids and alkalis: vomiting cannot be induced, gastric lavage through a tube lubricated with vegetable oil after the administration of a narcotic analgesic is the only indication for giving milk. For acid poisoning - antacids, for alkali poisoning - citric or acetic acid.

III... Removal of absorbed OM from the body

a) forced diuresis (conditions: sufficient renal blood flow and glomerular filtration; pour in-pour out 20-25 liters in 24 hours)

b) peritoneal hemodialysis

c) hemosorption

d) exchange blood transfusion

e) forced hyperventilation

IV... Symptomatic therapy of functional disorders.

Antidotes: 1) toxicotropic - binding, neutralizing and preventing absorption of OM: acting on the principle of activated carbon, acting on the chemical principle (unitiol, penicillamine, pentacin)

2) toxicokinetic - accelerate the biotransformation of OM (trimedoxime bromide, sodium thiosulfate, ethanol, AO)

3) pharmacological - atropine, naloxone

4) immunological antidotes

Unithiol, succimer - binds heavy metals, metalloids, cardiac glycosides. Esmolol binds theophylline, caffeine. Calcium trisodium pentotate - forms complexes with bivalent and trivalent metals.

49. The recipe and its structure. General rules for writing a prescription. State regulation of the rules for prescribing and dispensing drugs.

Recipe- this is a written appeal from a doctor to a pharmacist with a requirement to release the medicine in a certain form and dosage, indicating the method of its use

The following parts are distinguished in the recipe:

1. Inscriptio - title, inscription. The date of issue of the prescription, surname, initials and age of the patient, surname and initials of the doctor are written here.

2. Invocatio - contacting a pharmacist. It is expressed by the word “Recipe” (take) or by an abbreviation (Rp.)

3. Designatio materiarum - designation or name of medicinal products with indication of their doses. In a complex recipe, the listing of medicinal substances is done in a specific sequence. The first is the main drug substance (basis). Then the adjuvans are written. After that, the ingredients that correct the taste, smell, color of the medicine (corrigens) are indicated. The last to write are the substances that give the drug a certain dosage form (constituens).

4. Subscriptio - prescription (indication) to the pharmacist. It indicates the dosage form, pharmaceutical operations required for its manufacture, the number of dispensed doses of the drug.

5. Signatura - an instruction to the patient on how to use the medicine.

6. Subscriptio medici - signature of the doctor who wrote the prescription, his personal seal.

The doctor's address to the pharmacist, the name of the drugs included in the prescription, the name of the dosage form and the nature of the pharmaceutical operations are written in Latin. The name of medicines, botanical names of plants are written with a capital letter. The prescription for the patient is written in Russian or national languages.

General rules for prescribing:

1. The prescription is written on a special form, depending on the drug being written out, in clear handwriting, ink or ballpoint pen without corrections.

2. The prescription contains the date, month, year, surname, name, patronymic and age of the patient, surname, name and patronymic of the doctor. Then comes the text of the recipe, which lists the names of the substances included in the recipe in the genitive case, indicating their amount

3. The unit of mass in recipes is gram or UNIT.

4. If the maximum dose of poisonous and potent substances is exceeded, it is confirmed in words

5. The prescription is confirmed by the signature and personal seal of the doctor

The Republic of Belarus has State regulation of the rules for prescribing and dispensing drugs.

50. Rules for prescribing poisonous, narcotic and potent drugs.

List A includes drugs, the appointment, use, dosing and storage of which, due to their high toxicity, should be carried out with great care. The same list includes drugs that cause drug addiction.

List B includes drugs, the appointment, use, dosing and storage of which should be carried out with caution in connection with possible complications when using them without medical supervision.

For poisonous and potent drugs, the maximum higher single and daily doses have been established. These doses are for adults over 25 years of age. When recalculating doses for people over 60 years old, age sensitivity to different groups of drugs is taken into account. Doses of drugs that depress the central nervous system, as well as cardiac glycosides and diuretics are reduced by 50%, the doses of other poisonous and potent drugs are reduced to 2/3 of the adult dose. Doses of AB, sulfonamides and vitamins are usually the same for all age groups, starting from 25 years.

1. Narcotic drugs (List A) are prescribed on a prescription form 2. One form - one drug. There must be: the signature and seal of the attending physician, the signature of the head physician of the healthcare facility, the round stamp of the healthcare facility.

2. Poisonous drugs (list A), potent (list B) are prescribed on the prescription form of form 1. There must be a signature and personal seal of the doctor, the seal of the medical institution.

51. Medicines under control. Prescription drugs.

Narcotic, poisonous and potent drugs are under control (see section 20)

A) Medicines not registered in the Republic of Belarus and not authorized for official use

B) drugs at the request of patients and their relatives without examining the patient and establishing a diagnosis

C) prescriptions for narcotic drugs for injection, anesthetic ether, chloroethyl, pentamine, fluorothane, sodium oxybutyrate in ampoules, lithium oxybutyrate, barium sulfate for fluoroscopy.

52. Pharmacokinetic models (one-chamber and two-chamber), quantitative laws of absorption and elimination of drugs.

Single chamber model.

The whole organism is a single homogeneous container. Assumptions:

1) a rapid dynamic development is established between the content of the drug in the bloodstream and its concentration in extravascular tissues

2) The drug is quickly and evenly distributed throughout the blood volume

3) Elimination of drugs obeys first-order kinetics: the rate of decrease in the drug content in the blood is proportional to its concentration

If the mechanisms for elimination of the drug (biotransformation in the liver, renal secretion) are not saturated with the introduction of a therapeutic dose, a log-normal graph of changes in plasma concentration over time will be linear.

Incline lognormal axis - Kel, where Kel is the rate constant of elimination and has the dimension of time-1. The C0 value is obtained by extrapolating the graph to the intersection with the ordinate axis. Plasma drug concentration(Ct) at any time t after administration into the body is:

Ln Ct = Ln C0 - kt. The elimination constant Kel, Vd, and the total clearance (CL) are related by the expression: CL = k × Vd

Two-chamber model.

Often, after the drug enters the body, it is not possible to quickly achieve a balance between the drug content in the blood and its concentration in the extravascular fluid. Then it is believed that in the aggregate of tissues and biological fluids of the body, two chambers can be distinguished, which differ in the degree of accessibility for drug penetration. The central chamber includes blood (often with intensively perfused organs - liver, kidneys), and the peripheral chamber - the interstitial fluid of internal organs and tissues.

The resulting graph shows the initial The distribution phase ( The time required for the drug to reach an equilibrium state between the central and peripheral chambers and the following slow Elimination phase First order.

C0 value, obtained by extrapolation Elimination phases before crossing the ordinate. C0 is used to calculate the volume of distribution and the elimination constant. The formulas for calculating Ct and Cl given for the single chamber model are also applied during the elimination phase for drugs that satisfy the conditions of the two chamber model.

53. Selectivity and specificity of drug action. Therapeutic, side and toxic effects of drugs, their nature from the standpoint of the concept of receptors. A therapeutic strategy for combating side and toxic effects of drugs.

Specificity- this is when a drug binds to a type of receptor that is strictly specific to it.

Selectivity- this is when a drug is able to bind to one or more types of receptors more accurately than others.

It is more preferable to use the term selectivity, since it is unlikely that any drug molecule can bind to only one type of receptor molecule, since the number of potential receptors in each patient has astronomical significance.

Therapeutic action- the main desired pharmacological effect expected from a given pharmacological preparation.

Side effects- those effects that occur when substances are used in therapeutic doses and constitute the spectrum of their pharmacological action.

Toxic effects- undesirable effects manifested in this drug when it leaves the therapeutic range.

Relationships between the therapeutic and toxic effects of drugs based on the analysis of receptor-effector mechanisms:

1) therapeutic and toxic effects mediated by the same receptor-effector mechanism (prazosin acts as an alpha-selective antagonist on vascular SMC receptors and has a hypotensive effect in essential hypertension, but at a high dose, the patient may experience postural hypotension)

2) therapeutic and toxic effects mediated by identical receptors, but different tissues or different effector pathways (cardiac glycosides are used to increase the contractility of the myocardium, at the same time they disrupt the function of the gastrointestinal tract, vision due to blockade of Na + / K + -ATPase of the cell membrane)

3) therapeutic and toxic effects mediated by various types of receptors (for example, norepinephrine has a hypertensive effect through a1-Ap, but at the same time causes tachycardia through b1-Ap)

Therapeutic strategy to combat the therapeutic and side effects of drugs:

1.The drug should always be administered in the smallest dose that causes an acceptable therapeutic effect

2. Reduction of the dose of one drug due to the appointment of another drug with a similar effect, but through different receptors and with a different toxicity profile.

3. The selectivity of the drug action can be increased by controlling the drug concentration in the region of the receptors of various parts of the body (local use of drugs - inhalation use of salbutamol in bronchial asthma)

Dictionary of Medical Terms

pharmacology (pharmacologia; pharmacology + Greek logos doctrine, science)

a science that studies the effect of medicinal and other biologically active substances on the human body and animals.

Explanatory Dictionary of the Living Great Russian Language, Dal Vladimir

pharmacology

f. Greek part of medical science: about the action and the use of drugs, drugs. Pharmacologist, scientist in this area. Pharmacological readings. Pharmacolyte, fossil: arsenic acid lime. Pharmacopoeia J. list of medicines and drugs, which pharmacies are required to keep in readiness. Pharmacy, pharmaceuticals, the science of recognition, preparation and preparation of drugs. Pharmacist, pharmacist, pharmacist, apprentice apprentice, who is engaged in pharmacy. Pharmaceutical regulations.

Explanatory dictionary of the Russian language. D.N. Ushakov

pharmacology

pharmacology, pl. no, well. (from the Greek pharmakon - medicine and logos - teaching). The science of the action of medicinal substances on the body.

Explanatory dictionary of the Russian language. S.I.Ozhegov, N.Yu.Shvedova.

pharmacology

And, ace. The science of medicinal and other biologically active substances and their effect on the human and animal organism. Biochemical f Clinical f.

adj. pharmacological, th, th.

New explanatory and derivational dictionary of the Russian language, T. F. Efremova.

pharmacology

    A scientific discipline that studies medicinal substances and their effect on the body.

    An academic subject containing the theoretical foundations of this scientific discipline.

    colloquial A textbook outlining the content of this academic subject.

Encyclopedic Dictionary, 1998

pharmacology

PHARMACOLOGY (from the Greek. Pharmakon - medicine and ... logic) is a science that studies the effect of medicinal substances on the human body and animals. Systematized information on pharmacology is contained in the ancient Egyptian papyri, the works of Hippocrates, Dioscorides, and others. Paracelsus developed the concept of drug dosage. Experimental pharmacology has been developing since mid. 19th century Directions of modern pharmacology - the doctrine of the absorption, distribution and biotransformation of medicinal substances in the body; about the biochemical mechanisms of their action; study of drugs in clinical practice (clinical famacology). An important task of veterinary pharmacology is the search for drugs to stimulate the growth and productivity of animals. Pharmacology is closely related to pharmaceutical chemistry and other areas of science that study medicinal substances: physiology, pathological physiology, biochemistry, etc.

Pharmacology

Greek pharmakon - medicine and ... logic), biomedical science about medicinal substances and their effect on the body; in a broader sense - the science of physiologically active substances in general. The first systematized information about medicinal substances is contained in Egypt. Ebers papyrus (17th century BC); about 300 medicinal plants are mentioned in the writings of Hippocrates, their detailed descriptions were given by the ancient Greek physicians Theophrastus (372-287 BC) and Dioscorides (1st century AD). Composition of the last "Materia medica" ("Medical substance studies") until the 19th century. served as a synonym for the science of medicine, later named F. The information about medicinal plants contained in the works of Galen and Ibn Sina, and the works of Paracelsus, were of great importance for the development of F.. The beginning of modern experimental pharmacology was laid by R. Buchheim (Dorpat) in the middle of the 19th century. Its development was facilitated by O. Schmideberg, G. Meyer, V. Straub, P. Trendelenburg, K. Schmidt (Germany), A. Keschny, A. Clarke (Great Britain), D. Bove (France), K. Geimans (Belgium) , O. Levy (Austria) and others. In Russia in the 16-18 centuries. information about medicinal plants was placed in various "herbalists" and "greenery". In 1778 the first Russian was published. Pharmacopoeia "Pharmacopoea Rossica". In the 2nd half of the 19th - early 20th centuries. experimental phytography was developed (V. I, Dybkovsky, A. A. Sokolovsky, I. P. Pavlov, N. P. Kravkov, and others).

In modern physics, several directions are distinguished: pharmacodynamics - the actual doctrine of the effect of medicinal substances on the body; pharmacokinetics - the doctrine of their absorption, distribution and biotransformation in the body; molecular physics - the doctrine of the biochemical mechanisms of action of medicinal substances. The study of drugs in clinical practice and their final approbation is the subject of clinical F.

In the USSR, scientific research on F. is carried out at the Institute of Pharmacology of the Academy of Medical Sciences of the USSR and the All-Union Scientific Research Institute of Chemical and Pharmaceutical Sciences. S. Ordzhonikidze (Moscow), Kharkov Chemical-Pharmaceutical Institute, etc., at the departments of medical and pharmaceutical universities. Philosophy is taught in medical and pharmaceutical institutes and schools. The main research centers abroad: the F. institutes in Krakow, Prague, and Berlin; pharmacological laboratories at the Medical Center in Bethesda (USA), at the Mill Hill Institute (London), at the Higher Institute of Sanitation (Rome), the Max Planck Institute (Frankfurt am Main), the Karolinska Institute (Stockholm). F. is taught at the corresponding departments of the medical faculties of universities.

The main periodicals in the USSR and abroad: Pharmacology and Toxicology (Moscow, since 1938); Acta pharmacologica et toxicologica (Cph., From 1945); "Archives internationales de pharmacodynamie et detherapie" (P., from 1894); Arzneimittej √ Forschung (Aulendorf. C 1951); Biochemical Pharmacology (Oxf., From 1958): British Journal of Pharmacology and Chemotherapy (L., from 1946); Helvetica physiologica et pharmacologica acta (Basel, since 1943); Journal of Pharmacology and Experimental Therapeutics (Baltimore, from 1909); “Naunyn √ Schmiedeberg's Archiv fur experimentelle Pathologie und Pharmacologie” (Lpz., 1925) (in 1873-1925 √ “Archiv fur experimentelle Pathologie und Pharmakologie”). Physiology specialists in the USSR are united in the All-Union Scientific Society of Pharmacologists (since 1960), which is a member of the International Union of Pharmacologists, created in 1966; International congresses of pharmacologists are held every 3 years.

Lit .: Zakusov V.V., Pharmacology, 2nd ed., M., 1966; his, Pharmacology in the USSR for 50 years, "Pharmacology and toxicology", 1967, no. 30; Anichkov S.V., Belenky M.L., Textbook of pharmacology, 3rd ed., L., 1969; Albert E., Selective toxicity, M., 1971; Mashkovsky M.D., Medicines, 7th ed., P. 1√2, M., 1972; Goodman L. S., Oilman A., The pharmacological basis of therapeutics, 3rd ed., N. Y., 1965; Drill V. A., Pharmacology in medicine, 4th ed., N. Y., 1971; Drug Design, ed. by E. J. Ariens, v. 1√3.5, N. Y. √ L., 1971√75.

V.V. Zakusov.

Lit .: Mozgov I. Ye., Fifty years of Soviet veterinary pharmacology, "Veterinary", 1967, no. 10, p. 60√65; his, Pharmacology, M., 1974; Chervyakov D.K., Evdokimov P.D., Vishker A.S., Medicines in veterinary medicine, M., 1970.

Examples of the use of the word pharmacology in the literature.

And the investigator appointed an expert commission consisting of the chief forensic expert of the Ministry of Health of the Republic, head of the department pharmacology Medical Institute, Assistant of the Department of Surgery, Faculty of Advanced Training for Doctors, Forensic Histologist, Chemist and other specialists.

In developed countries, with their chemicalization, developed pharmacology, by the automation of everyday life, frank obesity and dullness occurs.

Various allopathic reference books on pharmacology describe the effect of drugs on the disease - this is an unscientific approach and a rather shaky help for medical practice.

An example is the transformation of such initially purely tactical techniques as presentation for identification, an investigative experiment, verification of testimony on the spot, seizure of samples, into independent procedural actions. conduct, methods and methods of achieving the goals of legal regulation In contrast to forensic science, such auxiliary sciences as forensic medicine, forensic psychiatry, forensic chemistry are usually classified as natural sciences, considering the first and second as special branches of general medicine, and the third as a branch of chemistry or pharmacology This rightly emphasizes that these sciences predominantly contain data from medicine or chemistry, adapted to resolve issues related to the study of evidence.

The next month, he tried on himself auromycin, bacitracin, fluoride with tin, hexidresorcinol, cortisone, penicillin, hexachlorophene, shark liver extract and 7312 other inventions of the world pharmacology.

Using the method of isolating medicinal activity when testing medicines on a healthy person, as Hahnemann pointed out, his students and homeopathic physicians subsequently replenished the work he had begun, testing new and testing old medicines, and gradually, thus, enriched the homeopathic pharmacology- PHARMACODYNAMICS.

Eight years ago I became a professor pharmacology and Herbal Science at the Faculty of Medicine, University of Heidelberg.

Pharmacology, sociology, physiology, not to mention autology, neurotheology, metachemistry, mycomysticism, and finally - he glanced to the side, as if wishing to be alone with his thoughts about Lakshmi - and finally, about science, according to which it is too early for us all or later you have to take an exam - I'm talking about thanatology.

However, the most conclusive expression of the strength of this effect at a distance was the pronounced positive shifts in the growth of the control group of rauwolfia at the Institute pharmacology on the street

The GPV of Russia and the Prosecutor General of Kyrgyzstan, a violation of republican legislation, according to which confiscated drugs must be transferred to law enforcement agencies as material evidence prior to a court decision, and then used in pharmacology.

Just before the development and aging model outlined in these essays was created before pharmacology no task was set to search for funds that would have the property of lowering the threshold of sensitivity of the hypothalamus to regulatory influences.

At different stages of the development of medical science, based on the achievements of physiology, biochemistry, physical chemistry, quantum pharmacology, biophysicists, tried to compare the effect of small doses of drugs with the effect of vitamin, hormonal, enzyme preparations and other drugs.

PROCESS DIAGRAMS Methods for coordinating knowledge CATALOGING SCIENTIFIC DATA SYSTEMATIZING SCIENTIFIC DATA Stress concept Pharmacology steroid hormones 8.

PHARMACOLOGY is the science of the interaction of chemical compounds with living organisms. Basically, pharmacology studies drugs used for the prevention and treatment of various pathological conditions.
Pharmacology is a biomedical science closely related to various areas of theoretical and practical medicine. Pharmacology, on the one hand, relies on the latest achievements of such sciences as physical chemistry, biochemistry, microbiology, biotechnology, etc., and on the other hand, it has a revolutionary, without exaggeration, influence on the development of related biomedical disciplines: physiology, biochemistry, various areas of practical medicine. So, with the help of synaptically active substances, it was possible to reveal the mechanisms of synaptic transmission, to study in detail the functions of various parts of the central nervous system, to develop theoretical prerequisites for the treatment of mental diseases, etc. The progress of pharmacology is also of great importance for practical medicine. Suffice it to recall how important it was and remains to this day the introduction into medical practice of drugs for anesthesia, local anesthetics, the discovery of penicillin, etc.
Due to the great importance of pharmacotherapy for practical medicine
dicina, knowledge of the basics of pharmacology is absolutely necessary for
a doctor of any specialty.
The most important task of pharmacology is the search for new drugs. Currently, the development, clinical trials and introduction of drugs into practice are carried out in many directions: experimental pharmacology, clinical pharmacology, toxicology, pharmacy, psychopharmacology, chemotherapy of infections, tumor diseases, radiation and environmental pharmacology, etc.
The history of pharmacology is as long as the history of mankind. The first drugs were obtained, as a rule, from plants empirically. Currently, the main way of creating new drugs is directed chemical synthesis, however, along with it, there is also the isolation of individual substances from medicinal raw materials; the release of medicinal substances from the waste products of fungi, microorganisms, biotechnological production.
Search for new connections
I. Chemical synthesis
1. Directed synthesis
- reproduction of biogenic substances (AH, NA, vitamins);
- creation of antimetabolites (SA, antineoplastic drugs, ganglion blockers);
- modification of molecules with known biological activity (HA-synthetic HA);
- synthesis based on the study of the biotransformation of a substance in the body (prodrugs, agents that affect the biotransformation of other substances).
2. Empirical way: random finds, screening of various chemical compounds.
II. Isolation of individual medicinal substances from medicinal raw materials
1. Vegetable;
2. Animal;
3. Mineral.
III. Isolation of drugs from the waste products of microorganisms, biotechnology (antibiotics, hormones, monoclonal antibodies to tumor cells in combination with a drug, etc.)
The creation of a new drug substance goes through a number of stages, which can be schematically represented as follows:
Idea or hypothesis
Creation of substance
Animal research
1. Pharmacological: assessment of the expected main effect;
classification of other effects by organs and systems; ...
2. Toxicological: acute and chronic toxicity. Causes
death of animals: biochemical, physiological and morphological methods of assessment.
3. Special toxicological: mutagenicity, carcinogenicity
(two species of animals, histological examination of 30 tissues with chronic administration), influence on reproductive processes (ability to conceive, embryotoxicity, teratogenicity).
Clinical trials
1. Clinical pharmacology (on healthy volunteers):,;
2. Clinical studies (on patients): pharmacodynamics,;
3. Official clinical trials (on patients): blind and double-blind control, comparison with the action of other medicinal substances - clinical practice;
4. Post-registration studies.


1. Routes of drug administration. Suction. The existing routes of administration of medicinal substances are divided into
enteral (through the gastrointestinal tract) and parenteral (bypassing
gastrointestinal tract).
The enteral routes include: introduction through the mouth - orally (per os), under the tongue (sublingual), into the duodenum (duodenally), into the rectum (rectally). The most convenient and common route of administration is through the mouth (oral). At the same time, sterility conditions, the participation of medical personnel, and special devices (as a rule) are not required. When administered orally, the substance reaches the systemic circulation by absorption.
Absorption to a greater or lesser extent occurs along the entire gastrointestinal tract, but it occurs most intensively in the small intestine.
With sublingual administration of the substance, absorption is fast enough. In this case, the drugs enter the systemic circulation, bypassing the liver, and are not exposed to the action of the gastrointestinal tract.
Sublingual substances with high activity are prescribed, the dose of which
rykh is very small (low absorption intensity): nitroglycerin, certain hormones.
A number of medicinal substances, such as acetylsalicylic acid, derivatives of barbituric acid, are partially absorbed in the stomach. Moreover, they, being weak acids, are in an undissociated form and are absorbed by simple diffusion.
When introduced into the rectum (per rectum), a significant part (up to
50%), medicinal substances enter the bloodstream bypassing the liver. In addition, in the lumen of the rectum, the drug is not exposed to the action of the gastrointestinal tract. Absorption is carried out by simple diffusion. Rectally medicinal substances are used in suppositories (suppositories) or medicinal enemas. Moreover, depending on the nature of the pathological process, substances can be prescribed for both systemic and local exposure.
The following absorption mechanisms are distinguished.
1. Passive diffusion through the cell membrane. Determined by the concentration gradient on both sides of the membrane. By passive diffusion, lipophilic non-polar substances are absorbed, which are readily soluble in the lipid bilayer of the membrane. The higher the lipophilicity, the better the substance penetrates the membrane.
2. Filtration through protein (hydrophilic) pores of the membrane. Depends on hydrostatic and osmotic pressure. The diameter of the pores in the membrane of intestinal epithelial cells is small (0.4 nm), so only small molecules can penetrate through them: water, some ions, a number of hydrophilic
substances.
3. Active transport using specific transport systems of the cell membrane. Active transport is characterized by selectivity for a specific substance, the possibility of competition of various substrates for the transport mechanism, saturation and energy dependence of the transfer of substances against the concentration gradient. In this way, some hydrophilic molecules, sugars, pyrimidines are absorbed.
4. Pinocytosis is carried out due to invagination of the cell membrane, the formation of a transport pinocytosis vesicle containing the transported substance and fluid, its transfer through the cytoplasm to the opposite side of the cell (from luminal to basal) and exocytosis of the contents of the vesicle outward. Vitamin B12 (in combination with Castle's intrinsic factor) and some protein molecules are absorbed by pinocytosis.
The main mechanism of drug absorption in the small intestine is passive diffusion. It is important to note that from the small intestine, substances with the blood flow enter the liver, where some of them are inactivated; in addition, part of the substance directly in the intestinal lumen is exposed to the action of the digestive system and is destroyed. Thus, only a part of the orally administered dose of the drug enters the systemic circulation (from where the drug is distributed throughout the body). That part of the medicinal substance
VA that has reached systemic blood flow in relation to the initial dose
drug is called bioavailability. Bioavailability is expressed as a percentage:
the amount of substance in the systemic circulation (max) x 100%
injected amount of substance
Factors affecting bioavailability
1. Pharmaceutical factors. The amount of the medicinal substance,
released from the tablet depends on the manufacturing technology: solubility, fillers, etc. Different branded tablets of the same substance (eg, digoxin) can take such different forms that they can cause very different effects.
2. Biological factors associated with bowel function. To them
the destruction of substances in the gastrointestinal tract itself, disturbing
absorption due to high peristalsis, binding of medicinal substances with calcium, iron, various sorbents, as a result of which they cease to be absorbed.
3. Presystemic (first pass) elimination. Some ve-
substances have a very low bioavailability (10-20%), despite the fact that it is well absorbed in the gastrointestinal tract. This is due to the high degree of their metabolism in the liver.
It should be borne in mind that in liver diseases (cirrhosis), the destruction of medicinal substances is slow, and therefore even the usual dosage can cause a toxic effect, especially with repeated administration.
Parenteral routes of administration of medicinal substances: subcutaneous, intramuscular, intravenous, intraarterial, intraperitoneal, inhalation, subarachnoid, suboccipital, intranasal, application to the skin (mucous membranes), etc. The choice of a specific route of administration is determined by the properties of the drug itself (for example, complete destruction in the gastrointestinal tract) and the specific therapeutic goal of pharmacotherapy.
Distribution of medicinal substances in the body.
Biological barriers. Escrow
From the blood, the drug enters the organs and tissues. Most medicinal substances are distributed unevenly in the body, since they pass through the so-called biological barriers in different ways: the capillary wall, cell membrane, blood-brain barrier (BBB), placenta and other histo-hematic barriers. The capillary wall is sufficiently permeable to most medicinal substances; substances penetrate through the plasma membrane either by means of special transport systems, or (lipophilic) by simple diffusion.
The BBB is of great importance for the distribution of various medicinal substances. It should be noted that polar compounds pass poorly through the BBB, while non-polar (lipophilic) compounds pass relatively easily. The placental barrier has similar properties. When prescribing drugs, the physician needs to know exactly about the ability of the substance to penetrate or not penetrate the appropriate barrier.
The distribution of the administered drug depends to a certain extent on its deposition. Distinguish between cellular and extracellular depots. The latter include blood proteins such as albumin. Binding to albumin for some drugs can reach 80-90%. Medicines can be deposited in bone tissue and dentin (tetracycline), in adipose tissue (deposition of lipophilic compounds - drugs for anesthesia). The deposition factor has a certain value for the duration of the drug's action.
It should be noted that the distribution of a substance in certain organs and tissues does not characterize its action, which depends on the specific sensitivity of the corresponding biological structures to it.
Biotransformation of medicinal substances in the body
Most of the medicinal substances that have entered the body undergo biotransformation, i.e. certain chemical transformations, in a number of cases as a result of which they, as a rule, lose their activity; however, as a result of bioransformation of the drug substance, a new, more active compound is formed (in this case, the administered drug is a so-called precursor or prodrug).
The most important role in biotransformation processes is played by microsomal livers, which metabolize substances foreign to the body (xenobiotics) of a hydrophobic nature, converting them into more hydrophilic compounds. Mixed action microsomal oxidases without substrate specificity oxidize hydrophobic xenobiotics with the participation of NADPH, oxygen and cytochrome P450. Inactivation of hydrophilic substances occurs with the participation of non-microsomal enzymes of different localization (liver, gastrointestinal tract, blood plasma, etc.).
There are two main types of drug transformation:
1. metabolic transformation,
2. conjugation.
Medicinal substance
———————- —————————
| Metabolic | | Conjugation: |
| transformation: | | - with glucuronic acid; |
| - oxidation; | | - with sulfuric acid; |
| - recovery ————- - with glutathione; |
| hydrolase | | - methylation; |
| | | - acetylation |
———————- —————————

METABOLITES CONJUGATES
EXCRETION
The excretion of most medicinal substances is carried out through the kidneys and liver (with bile into the gastrointestinal tract). The exception is volatile gaseous substances used for anesthesia - they are released mainly by the lungs.
Water-soluble, hydrophilic compounds undergo excretion through the kidneys by filtration, reabsorption, secretion in various combinations. It is clear that a process such as reabsorption significantly reduces the excretion of a drug from the body. It should be borne in mind that the reabsorption process significantly depends on the polarity (ionized or non-ionized form) of the substance. The higher the polarity, the worse the reabsorption of the substance. For example, with an alkaline reaction of urine, weak acids are ionized and, therefore, are less reabsorbed and to a greater extent excreted. These are, in particular, barbiturates and other hypnotics, acetylsalicylic acid, etc. This circumstance is important to consider in case of poisoning.
If the drug is hydrophobic (lipophilic), then it cannot be excreted in this form through the kidneys, since it undergoes almost complete reabsorption. Such a substance is excreted through the kidneys only after the transition to the hydrophilic form; this process is carried out in the liver by biotransformation of this substance.
A number of drugs and products of their transformation are excreted in significant quantities with bile into the intestines, from where they are partially excreted with excrement, and partly reabsorbed into the bloodstream, re-enters the liver and excreted into the intestines (the so-called enterohepatic recirculation). It should be emphasized that the consumption of fiber and other natural or artificial sorbents in food, as well as the acceleration of gastrointestinal motility, can significantly accelerate the elimination of these drugs.
One of the most common pharmacokinetic parameters is the so-called half-life (t1 / 2). This is the time during which the content of the substance in the blood plasma is reduced by 50%.
This decrease is due to both biotransformation processes and drug excretion. Knowledge (t1 / 2) facilitates the correct dosage of the substance to maintain its stable (therapeutic) concentration in blood plasma.


Qualitative aspects of pharmacotherapy.
Types of drug action
Distinguish between local and resorptive; direct and reflex action of drugs.
The action of a substance that occurs at the site of its application is called local. For example, enveloping substances, a number of external anesthetics, various ointments, etc. act locally.
The action of a substance that develops after its absorption (resorption) is called resorptive.
With both local and resorptive action, drugs can have either a direct or reflex effect. Direct influence is realized by direct contact with tissue. organo target. For example, adrenaline has a direct effect on the heart, increasing strength and heart rate. However, the same adrenaline, reflexively increasing the tone of the vagus nerve, can cause bradycardia after a while. Reflexive substances such as the so-called respiratory analeptics (cytiton, lobelin), which, when administered intravenously, stimulate the respiratory center of the medulla oblongata by stimulating the receptors of the sino-carotid zone.
Mechanisms of drug action
There are several main types of drug action.
I. Action on cell membranes:
a) effect on receptors (insulin);
b) impact on ion permeability (directly or through enzyme systems - transport ATPases, etc. - calcium channel blockers, cardiac glycosides;
c) the effect on the lipid or protein components of the membrane (drugs for anesthesia).
II. Effect on intracellular metabolism:
a) the effect on the activity of enzymes (hormones, salicylates, aminophylline, etc.);
b) impact on protein synthesis (antimetabolites, hormones). III. Action on extracellular processes:
a) violation of the metabolism of microorganisms (antibiotics);
b) direct chemical interaction (antacids);
c) the osmotic effect of substances (laxatives, diuretics), etc.
Let us dwell in more detail on the interaction of drugs with receptors and their effect on the activity of enzymes.
Receptors are called active groups of substrate macromolecules (usually membranes) with which the drug interacts. More often we will talk about receptors for neurotransmitters and neuromodulators. So, on the postsynaptic membrane and outside it, various types of receptors can be located. Depending on the name of the ligand (a substance that interacts with the receptor), they distinguish: adreno-, choline-, dopamine, histamine, opiate and other receptors. Most often, the receptors are membrane lipoprotein complexes. The number of receptors on the cell membrane is not constant; it depends on the amount and duration of action of the ligand. There is an inverse relationship between the amount of ligand (agonist) and the number of receptors on the membrane: with an increase in the amount or duration of use of a synaptically active substance, the number of receptors to it decreases sharply. Which leads to a decrease in the effect of the drug. This is a phenomenon called tachyphylaxis. On the contrary, with prolonged action of the antagonist (as with denervation), the number of receptors increases, which leads to an increase in the effect of endogenous ligands (for example, after prolonged use of beta-blockers, their withdrawal leads to an increase in the sensitivity of the myocardium to endogenous catecholamines - tachycardia develops, in some cases - arrhythmias, etc.).
The affinity of a substance (ligand) for a receptor, leading to the formation of a ligand-receptor complex, is denoted by the term affinity. The ability of a substance, when interacting with a receptor, to cause one or another effect is called internal activity.
Substances that, when interacting with receptors, cause changes in them, leading to a biological effect similar to the effect of a natural mediator or hormone, are called agonists. They also have inner activity. If an agonist, interacting with a receptor, causes the maximum effect, it is called a full agonist. Unlike full agonists, partial agonists do not produce maximum effect when interacting with receptors.
Substances that do not cause an appropriate effect when interacting with receptors, but reduce or eliminate the effects of agonists, are called antagonists. If they (bind) to the same receptors as agonists, then they are called competitive antagonists; if
- with other parts of the macromolecule that are not related to the receptor part, then these are non-competitive antagonists.
If the same compound simultaneously possesses the properties of both an agonist and an antagonist (i.e., it produces an effect, but eliminates the action of another agonist), then it is designated an agonist-antagonist.
The drug substance can interact with the receptor using covalent bonds, ionic (electrostatic interaction), van der Waals, hydrophobic and hydrogen bonds.
Depending on the strength of the "substance-receptor" bond, a distinction is made between the reversible (typical for most cases) and irreversible (covalent bond) action of medicinal substances.
If a substance interacts with one type of receptor and does not affect others, then the action of this substance is considered selective (selective) or, better to say, predominant, because there is practically no absolute selectivity of the action of substances.
The interaction of both the natural ligand and the agonist with the receptor causes various effects: 1) direct change in the ionic permeability of the membrane; 2) action through the system of so-called "secondary messengers" - G-proteins and cyclic nucleotides; 3) influence on DNA transcription and protein synthesis (Dale). In addition, the drug can interact with the so-called nonspecific binding sites: albumin, tissue glycosaminoglycans (GAGs), etc. These are the places where matter was lost.
The interaction of a drug with enzymes in many ways
similar to its interaction with the receptor. Drugs can change
enzyme activity, since they may be similar to natural
substrate and compete with it for the enzyme, and this competition
can also be reversible and irreversible. It is also possible
allosteric regulation of enzyme activity.
So, the mechanism of action of a medicinal substance from the point of view of qualitative aspects determines the direction of influence on a particular process. However, for each drug there are also quantitative criteria that are very important, since the dose of the substance must be carefully selected, otherwise the drug will either not provide the desired effect, or it will cause intoxication.
In the area of ​​the so-called therapeutic doses, there is a certain proportional dependence of the effect on the dose (the so-called dose-dependent effect of the substance), however, the nature of the dose-effect curve is individual for each drug. In general, we can say that with an increase in the dose, the latency period decreases, the severity and duration of the effect increase.
At the same time, with an increase in the dose of the drug, an increase in a number of side and toxic effects is also noted. In addition, a further increase in the dose of the drug (after reaching the maximum therapeutic effect) does not lead to an increase in the effect, but various undesirable reactions are observed. For practice, the ratio of doses of the drug caused by the therapeutic and toxic effects is important. Therefore, Paul Ehrlich introduced the concept of "therapeutic index", which is equal to the ratio:
maximum tolerated dose
maximum therapeutic dose
In fact, such an index in patients is not determined, but in animals it is determined by the ratio
LD50x100%,
ED50
where LD50 is the dose that causes the death of 50% of animals;
ED50 is the dose that produces the desired effect in 50% of animals.
Among the doses used in clinical practice, there are:
- a single dose;
- daily dose (pro die);
- average therapeutic dose;
- the highest therapeutic dose;
- course dose.
Calculation of doses: in addition to standard pharmacopoeial ones, in some cases the dose is calculated per kg of body weight or body surface area.
Re-use of medicines
With repeated use of medicinal substances, both weakening and intensifying effects of medicinal substances can be observed.
I. Weakening of the effect: a) addiction (tolerance); b) tachyphylaxis.
II. Strengthening the effect - cumulation a) functional (ethyl alcohol), b) material (glycosides)].
III. A special reaction that develops with repeated use of drugs is drug dependence (mental and physical), in which a "withdrawal syndrome" develops. Withdrawal syndrome, in particular, is characteristic of antihypertensive substances, beta-blockers, agents that depress the central nervous system; hormones (HA).
Drug interaction
As a rule, during treatment, the patient is prescribed not one, but several drugs. It is important to consider the ways in which medicinal substances interact with each other.
Distinguish:
I. Pharmaceutical interactions;
II. Pharmacological interactions:
a) based on the interaction on pharmacokinetics (absorption,
binding, biotransformation, enzyme induction, excretion);
b) based on the mutual influence on pharmacodynamics;
c) based on chemical and physical interaction in the internal environment of the body.
The most important pharmacodynamic interaction. At the same time, the following types of interaction are distinguished:
I. Synergism: summation (additive effect) - when the effect from
the use of two drugs is equal to the sum of the effects of two drugs A and
B. Potentiation: the combined effect is greater than the simple sum of effects
preparations A and B.
II. Antagonism: chemical (antidote); physiological (be-
ta-blockers - atropine; hypnotics - caffeine, etc.).
The main types of drug therapy:
- Preventive use of medicines;
- Etiotropic therapy (AB, CA, etc.);
- Pathogenetic therapy (antihypertensive drugs);
- Symptomatic therapy (analgesics);
- Substitution therapy (insulin).
The main and side effects of medicinal substances. Allergic reactions. Idiosyncrasy.
Toxic effects
The main effect of medicinal substances is determined by the purpose of pharmacotherapy, for example, the appointment of analgesics for the purpose of pain relief, levamisole as an immunomodulator or as an anthelmintic agent, etc. Along with the main one, almost all substances have a number of side effects. Side effects (of non-allergic nature) are due to the spectrum of pharmacological action of a particular drug. For example, the main effect of aspirin is an antipyretic effect, a side effect is a decrease in blood clotting. Both of these effects are due to a decrease in the metabolism of arachidonic acid.
There are primary and secondary side effects of drugs. The primary one arises as a direct consequence of the action of this drug on any substrate or organ: for example, when using the drug atropine in order to reduce gastric secretion, dry mouth, tachycardia, etc. Secondary - refers to indirect adverse effects - for example, dysbiosis and candidiasis with antibiotic therapy. Adverse effects are very diverse, and include inhibition of hematopoiesis, damage to the liver, kidneys, hearing, etc. With prolonged use of various drugs, secondary diseases arise (steroid diabetes, immunodeficiencies, aplastic anemias, etc.).
The negative effects of pharmacological drugs include allergic reactions of varying severity. It should be emphasized that the occurrence of allergic reactions does not depend on the dose of the drug; they can occur even during a cutaneous test. The most dangerous is anaphylactic shock that occurs when using penicillin and other drugs.
Idiosyncrasy - an atypical, often genetically determined, associated with a specific enzymopathy, the reaction of an individual to a drug. For example, in individuals with a deficiency of glucose-6-phosphate dehydrogenase, the use of sulfonamides can cause a hemolytic crisis.
All of these reactions occur mainly with the use of medium therapeutic doses. When using the maximum therapeutic doses or overdose, toxic effects occur - damage to the auditory nerve, arrhythmias, depression of the respiratory center, hypoglycemia, etc. Toxic effects can also be observed when using usual doses in patients with damage to the main excretory systems (liver, kidneys,) or the so-called "slow acetylators".
In addition to somatic toxic effects, there are toxic effects on the embryo and the fetus - embryo- and fetotoxicity. Although most drugs are tested for embryo fetotoxicity, however, in humans during pregnancy, these drugs, of course, have not been tested, therefore, it is better during pregnancy (especially in the first three months) to refrain from using any drugs other than those prescribed for health reasons.
Basic principles of treatment of acute drug poisoning
I. Delayed absorption of the drug into the blood
- vomiting, gastric lavage, activated carbon;
- sorbents;
- laxatives;
- tourniquet on a limb.
II. Removal of a toxic substance from the body
- forced diuresis;
- peritoneal dialysis, hemodialysis, plasmapheresis;
- hemosorption, etc .;
- blood substitution.
III. Neutralization of an absorbed medicinal (toxic) substance
- antidotes;
- pharmacological (physiological antagonists).
IY. Pathogenetic and symptomatic treatment of acute poisoning Control over the function of vital organs and homeostasis indicators
- central nervous system;
- breathing;
- of cardio-vascular system;
- kidneys;
- homeostasis: acid-base state, ionic and water balance, glucose, etc.
One of the most important measures is the prevention of acute poisoning (especially in children). Keep medicinal substances out of the reach of children.

Pharmacology - (Greek. Pharmacon - medicine) a science that studies the interaction of chemical compounds of biological and non-biological origin with the human and animal organisms.

The main task of pharmacology: search, development and study of new drugs for the prevention, treatment and diagnosis of various diseases and pathological conditions.

The range of issues studied by pharmacology:

- drug classification;

- pharmacodynamics, incl. mechanism of action;

- pharmacokinetics;

- indications and contraindications for use;

- side effects of drugs and complications;

- interaction of drugs with their combined administration;

- assistance in drug poisoning.

Pharmacology is divided into general and specific.

General pharmacology studies the general patterns of interaction of drugs with the body, i.e. pharmacodynamics and pharmacokinetics.

Private pharmacology studies the pharmacological properties of specific pharmacological groups and individual drugs.

Sections of pharmacology:

1. Pediatric Pharmacology - studies the features of the action of drugs on the child's body.

2. Perinatal pharmacology - studies the effect of drugs on the fetus (from 24 weeks to childbirth) and the newborn's body (in the first 4 weeks of life).

3. Geriatric pharmacology - studies the features of the action and use of drugs in elderly and senile people.

4. Pharmacogenetics - studies the role of genetic factors in the body's sensitivity to drugs.

5. Chronopharmacology - studies the dependence of the pharmacological effects of substances on daily and seasonal rhythms.

6. Clinical pharmacology - studies the effect of drugs on the body of a sick person.

7. Medicinal toxicology - studies the effects of toxic, lethal doses of drugs and methods of neutralizing the body in case of drug poisoning.

Pharmacodynamics.

Pharmacodynamics - a section of pharmacology that studies the totality of the effects caused by drugs, incl. mechanisms of their action.

The therapeutic and prophylactic effect of any drug is manifested by strengthening or inhibition of physiological or biochemical processes in the body. This is accomplished in the following way:

- By interaction of the drug with the receptor (drugs + R).

- By the action of drugs on the activity of enzymes (drugs + enzyme).

- By the action of drugs on biomembranes (drugs + biomembrane).

- Through the interaction of some drugs with other drugs or with endogenous substances.

1. Interaction of the drug with receptors.

Receptor Is a protein or glycoprotein with high sensitivity and affinity for a certain chemical compound, including drugs.

Agonist -A drug that, when interacting with receptors, causes a pharmacological effect.

Antagonist- a drug that reduces or completely eliminates the effect of another drug.

Antidotes- drugs that eliminate the action of other drugs that cause poisoning.

There are two types of antagonism:

- competitive (direct);

- non-competitive (indirect).

Competitive antagonism is carried out by the competition of different drugs for the binding sites on the same receptor, which leads to a decrease in the effects of one drug by another. Non-competitive antagonism is associated with various receptors.

Synergy -mutual enhancement of the pharmacological effect of one drug by another.

Summation- the total effect of two or more simultaneously applied drugs, which is equal to the arithmetic sum of the effects of each of these drugs.

Potentiation- this is when the total effect of the combined drugs is greater than the arithmetic sum of their pharmacological effects.

2. The effect of drugs on enzyme activity.

Some drugs are able to increase or decrease the activity of enzymes, thus providing their pharmacotherapeutic effect. For example, aspirin exhibits analgesic, anti-inflammatory and antipyretic effects due to its ability to selectively inhibit the enzyme cyclooxygenase.

3. Interaction with biomembranes.

A number of drugs are capable of changing the physicochemical properties of cell and subcellular membranes, thus changing the transmembrane ion current (Ca 2+, Na + , K +). This principle is the basis of the mechanism of action of antiarrhythmic crises of local anesthetics, calcium channel blockers and some other drugs.

4. Interaction of drugs with drugs.

According to the principle of action of antidotes. (see above)

Types of drug action.

The main one issuch effect of the drug, which the doctor expects when using it.

Undesirable:- lateral;

Allergic;

Toxic.

Side effect - this is a non-vital reaction of the body, due to the pharmacological properties of the drug, and is observed when it is used in doses recommended for treatment. They occur simultaneously with the main therapeutic effect. These reactions are not life-threatening and are sometimes used as the main action. For example, the side (hypnotic) effect of the anti-allergic agent diphenhydramine is often used as the main one.

Relative overdose - these are toxic reactions that can occur when even average therapeutic doses enter the body, if the patient has impaired functions of the organs metabolizing and excreting drugs.

Teratogenic action (tetas - freak) is an undesirable effect of drugs on the fetus, which leads to the birth of a child with anomalies or deformities.

Embryotoxic action - this is the toxic effect of drugs on the fetus up to 12 weeks of pregnancy.

Fetotoxic action - This is a toxic effect on the fetus after 12 weeks of pregnancy.

Mutagenic action - the ability of drugs to disrupt the genetic apparatus of germ cells, changing the genotype of the offspring.

Carcinogenic effect - the ability of substances to cause the formation of malignant tumors.

Local drug action - this is a manifestation of the therapeutic and prophylactic effect of drugs at the site of application (application) of drugs.

Resorptive action of drugs - manifestation of the pharmacotherapeutic effect of drugs after absorption of the drug into the systemic circulation.

Types of doses.

Threshold - this is the minimum dose of a drug that causes any biological effect.

Middle therapeutic - the dose of the drug that produces the optimal therapeutic effect.

Higher therapeutic - the dose that causes the greatest pharmacological effect.

Breadth of therapeutic action Is the interval between the threshold and the highest therapeutic dose.

Toxic- the dose at which symptoms of poisoning occur.

Deadly- the dose that causes death.

One-time- pro dosi - single dose.

Shock- the dose prescribed at the beginning of treatment, which is 2-3 times higher than the average therapeutic dose and is prescribed in order to quickly achieve the required concentration of drugs in the blood or other biological media.

Supportive- the dose prescribed after the shock, and it corresponds, as a rule, to the average therapeutic.

The effect of drugs when they are re-introduced into the body.

With repeated use, the effectiveness of drugs can change both upward and downward. Undesirable effects occur.

An increase in the pharmacological effect is associated with its ability to cumulate. Cumulation ( cumulatio ) Is an increase in the effect of drugs when they are reintroduced into the body.

Cumulation is of two types: material (physical) and functional.

Material cumulation- it is realized when an increase in the therapeutic effect occurs due to the accumulation of drugs in the body.

Functional cumulation- this is when an increase in the therapeutic effect and the appearance of symptoms of an overdose occurs faster than the accumulation of the drug itself in the body.

Addictive- This is a decrease in the pharmacological activity of the drug when it is re-introduced into the body.

Cross addictive - this is addiction to drugs of similar (close) chemical structure.

Lecture number 2.

GENERAL PHARMACOLOGY (continued).

Pharmacokinetics - This is a section of pharmacology that studies the various stages of the passage of a drug in the body: absorption (absorption), biotransport (binding to serum proteins), distribution to organs and tissues, biotransformation (metabolism), excretion (excretion) of drugs from the body.

Ways of introducing drugs into the body.

The route of administration of the drug into the body depends on:

- the speed and completeness of drug delivery to the focus of the disease;

- efficacy and safety of drug use, i.e. without complications of pharmacotherapy.

1. Enteral route of administration - the way drugs enter the body through the gastrointestinal tract.

The advantages of the enteral route of administration:

- ease of use;

- safety of use;

- manifestation of local and resorptive effects.

The enteral route includes:

- oral (per os ) - through the mouth (intragastrically);

- sublingual (Sub linqva) - under the tongue;

- intraduodenal ( Intra duodenum ) - into the duodenum.

- rectal (per rectum ) - through the rectum.

2. Parenteral route of administration - This is the entry of drugs into the body, bypassing the digestive tract.

The advantages of the parenteral route include:

- achieving an accurate dosage;

- fast implementation of the drug effect.

The parenteral route includes:

- intravenous administration;

- intra-arterial administration;

- intramuscular injection;

- subcutaneous administration;

- intratracheal administration;

- intravaginal administration;

- intraosseous administration.

Characterization of individual stages of pharmacokinetics.

1. Suction (absorption) - the process of drug delivery from the site of its introduction into the systemic circulation during extravascular administration.

The drug absorption rate depends on:

- dosage form of the drug;

- the degree of solubility of drugs in fats or in water;

- dose or concentration of drugs;

- route of administration;

- the intensity of the blood supply to organs and tissues.

The absorption rate for oral administration of drugs depends on:

- pH of the environment in various parts of the gastrointestinal tract;

- the nature and volume of the contents of the stomach;

- microbial contamination of the intestines;

- the activity of food enzymes;

- states of gastrointestinal motility;

- the interval between taking medicine and food.

The drug absorption process is characterized by the following pharmacokinetic parameters:

- Bioavailability (f) - the relative amount of the drug that comes from the injection site into the blood (%).

- Suction rate constant (K 01) - a parameter that characterizes the rate of drug intake from the injection site into the blood (h -1, min -1).

- Half-absorption period ( t ½ α ) - the time required for absorption from the injection site into the blood of ½ of the administered dose (h, min).

- Time to reach maximum concentration ( t max) - this is the time during which the maximum concentration of drugs in the blood is reached (h, min).

The intensity of the processes of absorption of drugs in children reaches the level of adults only by the age of three years. Up to three years of life, the absorption of drugs is reduced, mainly due to insufficient microbial contamination of the intestine, as well as due to a lack of bile formation. Absorption is also reduced in people over 55 years of age. Therefore, children and the elderly need to dose medications taking into account the age-related anatomical and physiological characteristics of the body.

2. Biotransport - reversible drug interactions with transport proteins of blood plasma and erythrocyte membranes.

The overwhelming majority of drugs (90%) interact reversibly with human serum albumin. In addition, drugs form reversible complexes with globulins, lipoproteins, glycoproteins. The concentration of the protein-bound fraction corresponds to the free fraction, i.e. not associated with the protein fraction: [C bond] = [C free].

Only the free (unbound to protein) fraction possesses pharmacological activity, and the bound fraction is a kind of reserve of the drug in the blood.

The associated part of the drug with the transport protein determines:

- the strength of the pharmacological action of the drug;

Biotransformation is carried out in 2 phases.

Reactions Iphases (biotransformation) - this is hydroxylation, oxidation, reduction, deamination, dealkylation, etc. In the course of reactions I phase, there is a change in the structure of the molecule L C so that it becomes more hydrophilic. This allows for easier excretion of metabolites from the body in the urine.

Reactions I phases are carried out with the help of enzymes of the endoplasmic reticulum (microsomal enzymes or enzymes of the monooxygenase system), the main of which is cytochrome P - 450. Medicines can both increase and decrease the activity of this enzyme. PM passed I phase, structurally prepared for reactions II phases of biotransformation.

During reactions IIphaseconjugates or paired compounds of the drug are formed with one of the endogenous substances (for example, with glucuronic acid, glutathione, glycine of sulfuric acid). The formation of conjugates occurs during the catalytic activity of one of the enzymes of the same name. So, for example, the drug + glucuronic acid conjugate is formed by the enzyme glucuronide transferase. The resulting conjugates are pharmacologically inactive substances and are easily excreted from the body with one of the excretions. However, not all of the administered drug dose undergoes biotransformation, some of it is excreted unchanged. - Elimination constant (To el ) - characterizes the rate of disappearance of the drug from the body by excretion and biotransformation (h -1, min -1).

- Half-elimination period (t 1/2 ) - this is the time of disappearance of the drug from the body by biotransformation and excretion of ½ of the administered or received and absorbed dose (h, min.).

Similar publications